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Drugs and surgical techniques may have harmful renal effects during the perioperative period. 
Traditional biomarkers are often insensitive to minor renal changes, but novel biomarkers may 




rane anesthesia as well as to determine the effect of F- on renal function and cellular integrity in 
 surgical patients.
A total of  patients undergoing either conventional (n = 75) or endoscopic (n = 68) inpa-
tient surgery were enrolled in four studies. The ketorolac and clonidine studies were prospec-
tive, randomized, placebo controlled and double-blinded, while the cigarette smoking studies 
were prospective cohort studies with two parallel groups.
As a sign of proximal tubular deterioration, a similar transient increase in urine N-acetyl-β-
D-glucosaminidase/creatinine (U-NAG/crea) was noted in both the ketorolac group and in the 
controls (baseline vs. at two hours of anesthesia, p = 0.05) with a . minimum alveolar con-
centration	hour	sevoflurane	anesthesia.	Uncorrelated	U-NAG	increased	above	the	maximum	
concentration measured from healthy volunteers (6. units L-) in 5/5 patients with ketorolac 
and in none of the controls (p = 0.02). As a sign of proximal tubular deterioration, 
U-glutathione transferase-α/crea (U-GST-α/crea) increased in both groups at two hours after 
	anesthesia	but	a	more	significant	 increase	was	noted	 in	 the	patients	with	ketorolac.	U-GST- 
α/crea increased above the maximum ratio measured from healthy volunteers in 7/5 patients 
with ketorolac and in /5 controls.
Clonidine diminished the activation of the renin-angiotensin aldosterone system during 
pneumoperitoneum; urine output was better preserved in the patients treated with clonidine 
(/5 patients developed oliguria) than in the controls (8/5 developed oliguria (p=0.005)). 
Most	patients	with	pneumoperitoneum	and	isoflurane	anesthesia	developed	a	transient	proximal	
tubular deterioration, as U-NAG increased above 6. units L- in /5 patients with clonidine 
and in 7/5 controls. In the patients receiving clonidine treatment, the median of U-NAG/crea 
was higher than in the controls at 60 minutes of pneumoperitoneum (p = 0.0), suggesting that 




7/25	smokers	with	sevoflurane	anesthesia.	All	five	patients	with	S-F-	≥	40	µmol L-, but only 
6/5 with S-F- less than 0 µmol L- (p = 0.00), developed a S-tumor associated trypsin in-
hibitor concentration above  nmol L- as a sign of glomerular dysfunction. As a sign of proxi-
mal tubular deterioration, U-β2-microglobulin increased in 2/5 patients with S-F- over 0 µmol 
L- compared to 2/5 patients with the highest S-F- less than 0 µmol L- (p = 0.005).
To	conclude,	sevoflurane	anesthesia	may	cause	a	 transient	proximal	 tubular	deterioration	
which may be worsened by a co-administration of ketorolac. Clonidine premedication prevents 
the activation of the renin-angiotensin aldosterone system and preserves normal urine output, 
but may be harmful for proximal tubules during pneumoperitoneum. Smoking induces the me-
6
tabolism	of	enflurane	but	not	that	of	sevoflurane.	Serum	F- of 0 µmol L- or higher may induce 
glomerular	dysfunction	and	proximal	tubular	deterioration	in	patients	with	sevoflurane	anesthe-
sia. The novel renal biomarkers warrant further studies in order to establish reference values for 
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The kidneys’ feedback systems are important for maintaining body homeostasis. The kidneys 
adjust the water, electrolyte, and acid-base balance, and remove waste products of metabolism. 
In addition, the kidneys regulate endocrine functions, such as erythropoiesis and renin- 
angiotensin-aldosterone system (RAAS) (Ganong 200). 
In Finland, 580 patients i.e. 68 per million adults received renal replacement therapy in 
200 (Finnish Registry of Kidney Disease 200). Although severe renal deterioration is a rare 
condition, acute renal failure (ARF) developing during surgery and leading to renal replacement 
therapy is an independent risk factor for mortality (Chertow et al. 998). 
In clinical practice urine output, serum creatinine (S-crea) and S-urea are used to assess renal 
function. However, these methods are insensitive to minor changes in renal function; almost 
half of renal glomerular function is lost when S-crea and S-urea increase (Kellen et al. 99, 
Star	1998).	Thus,	more	specific	and	sensitive	markers	are	needed.
Several biomarkers are released into the serum and urine when kidney function and cellular 
integrity is deteriorated. Glomerular function may be assessed using S-cystatin C and S-tumor 
associated trypsin inhibitor (S-TATI) (Tramonti et al. 997, Harmoinen 200). Proximal tubular 
dysfunction may be assessed with U-α-microglobulin/creatinine (U-α-MG/crea) (Teppo 
et al. 2000) and cellular integrity with U-N-acetyl-β-D-glucosaminidase/creatinine (U-NAG/
crea) (Higuchi et al. 995) and U-glutathione transferase-α (U-GST-α) ( (Branten et al. 2000). 
Urine glutathione transferase-π (U-GST-π) may be used to determine the distal tubular cellular 
integrity (Usuda et al. 999). However, these markers are primarily used in research and not in 
clinical practice.
Metabolism of anesthetic drugs produces substances, which may be toxic to the kidneys 




esthesia, high levels of S-F- can be found and renal proximal tubular damage markers are re-
leased	into	the	urine	(Higuchi	et	al.	1995,	Eger	et	al.	1997),	although	conflicting	results	have	
been published (Ebert et al. 998a).
Other factors, however, related to the patient, anesthesia and surgery may alter the risk for 
renal failure. Cigarette smoking is common among Finnish adults (Uutela and Koskinen 2002). 
Enzyme induction or inhibition by cigarette smoke may lead to altered metabolism of drugs 
(Vähäkangas	et	al.	1983,	Miller	1990).	Enflurane	and	sevoflurane	are	metabolized	in	the	liver	
by the enzyme, cytochrome P50 2E (CYP 2E), (Kharasch and Thummel 99, Kharasch et 





catecholamines and the synthesis of angiotensin II, which may induce renal vasoconstriction 
(Lameire et al. 2005). By preventing the synthesis of vasodilating prostaglandins (PGs) in the 
20
kidneys, NSAIDs predispose the kidneys to vasoconstriction and ischemia (Thadhani et al. 
996). 
Clonidine, an α2-adrenergic receptor agonist, decreases the need of anesthetics and opioids 
during surgery (Engelman et al. 989, De Deyne et al. 2000). Clonidine causes vasodilatation 
in renal arteries and may inhibit the effect of antidiuretic hormone (ADH) on collecting tubules 
(Reid et al. 979) and prevent the increase in serum noradrenaline concentration (Joris et al. 
998). During surgery, clonidine preserves normal urine output (Hamaya et al. 99). 
Laparoscopic	surgery	is	increasingly	used	for	abdominal	surgery.	The	surgical	visual	field	is	
created	 by	 insufflating	 carbon	 dioxide	 (CO2) into the peritoneal cavity. Pneumoperitoneum 
causes a release of catecholamines (Joris et al. 998), activates RAAS (Lindgren et al. 995), 
increases ADH secretion (Viinamäki and Punnonen 982) and compresses the kidney and renal 
vasculature (Doty et al. 2000). All these factors may induce renal ischemia and cause proximal 
tubular damage and diminished urine output.
This study evaluated the effects of different factors on renal function during the periopera-
tive	period	using	novel	and	sensitive	biomarkers	of	renal	function	and	cellular	integrity.	We	first	
examined	the	renal	effects	of	ketorolac	during	sevoflurane	anesthesia;	next,	we	examined	the	
renal effects of clonidine during laparoscopic cholecystectomy; and thirdly, we studied the ef-
fects of smoking on production of F-	after	enflurane	and	sevoflurane	anesthesia,	and	the	renal	
effects of the released F-.
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REVIEW OF THE LITERATURE
KIDNEY AND RENAL FUNCTION
The	filtering	capillary	network	of	a	nephron	is	called	a	glomerulus.	A	nephron,	numbering	one	
million in each kidney, consists of a glomerulus and a tubular system. The glomerulus is situ-
ated between an afferent and an efferent arteriole. The nephrons are divided into cortical and 
medullary nephrons, according to their position, length of Henle’s loops, and vascular supply. 
The majority of nephrons are situated in the cortical region gaining their blood supply from 
glomerular efferent arterioles. One seventh of the nephrons and their loop’s of Henle are in the 
medullary region and the arcuate artery (arteria arcuata) is the source of their blood supply. 
The	glomerular	filtrate	passes	to	the	proximal	tubule.	From	there	the	filtrate	passes	into	the	
loop of Henle, which dives towards the cortical or medullary region. The loop of Henle consists 
of two segments, the descending and ascending loops. The ascending loop is divided into two 
different parts, an initial thin segment that turns into a thick segment. 
The distal part of the tubule begins after the loop of Henle, near the cortical region. At the 
cortical region, the distal tubules join to form a collecting duct, entering the medullary area and 
coalescing to the renal pelvis (Tischer and Madsen 200). The juxtaglomerular apparatus, 
 situated in proximity of the distal tubule, consists of granular cells, which synthesize and release 
renin. Renin acts with the angiotensin converting enzyme to produce angiotensin II from angi-
otensinogen. Angiotensin II induces arteriolar vasoconstriction and aldosterone secretion in the 
adrenal cortex and ADH secretion in the pituitary gland. The RAAS increases blood pressure, 
decreases	glomerular	filtration	rate	(GFR)	and	increases	sodium	and	water	reabsorption	in	the	
collecting ducts (Ganong 200). 
Blood	 to	be	filtered	enters	 the	glomerulus	via	afferent	 and	 leaves	via	efferent	 arterioles.	
Blood for the tubular network comes from the glomerular efferent arterioles or arcuate arteries 
and follows the loops of Henle supplying deep medullary regions as vasa recta vessels 
(arteriolae and venae rectae). From there the blood enters the venous system (Ganong 200). 
Renal	blood	flow	(RBF)	varies	in	the	different	regions	of	the	kidney;	in	the	cortical	region,	
blood	flow	is	4	mL	min- g- of renal tissue and in the outer medullary region it is 2 mL min- 
g-	(Ganong	2003).	Although	the	kidneys	receive	one	fifth	of	cardiac	output	and	the	renal	basal	
oxygen consumption is one tenth of the total oxygen consumption of the body, the oxygen par-
tial pressure at the medullary vasa recta arterioles is low, approximately . kPa. Due to low 
oxygen partial pressure, the metabolically active proximal convoluted tubules and deep loops 
of Henle are vulnerable to ischemia (Kopolovic et al. 989, Brezis et al. 989).
Blood	flow	autoregulation	and	the	tubuloglomerular	feedback	mechanism	maintain	intrare-
nal	oxygen	homeostasis	 (Shipley	and	Study	1951).	The	blood	flow	 is	maintained	at	normal	
levels despite large variations in blood pressure by altering the arteriolar tone (renal autoregula-
tion). The mechanism of autoregulation is not completely understood. However, it is known that 
the autoregulatory response includes the action of the intrinsic renal vasoconstrictor angiotensin 
II, the effect of vasodilating renal PGs and the myogenic contractile response of the renal vas-
culature (Dibona and Sawin 200). In the case of decreased delivery of sodium and chloride 
ions to distal tubules or decreased blood pressure, the tubuloglomerular feedback mechanism 





sure is affected by pressure in afferent and efferent arterioles and glomerular oncotic pressure. 
Intense sympathetic or angiotensin II stimulation causes vasoconstriction in afferent arterioles 
and a drop in GFR. A lesser sympathetic or angiotensin II stimulation increases efferent arteri-
oles vascular tone, subsequently increasing GFR (Hall et al. 977).
The	majority	of	the	ultrafiltrate,	e.g.	ions,	amino	acids,	and	organic	solutes,	is	reabsorbed	in	
the proximal convoluted tubule (Ganong 200). There are several active transport systems in 
the	proximal	tubules,	which	reabsorb	solutes	from	tubular	fluid.	Reabsorption	occurs	against	a	
concentration gradient and is energy-dependent (Ganong 200).
The hyperosmotic medulla is created by the loops of Henle, which have segmentally differ-
ent permeability to water and active transport systems to sodium, chloride and urea in order to 
create	hyperosmotic	medulla.	In	the	vasa	recta	vessels,	 the	blood	flow	is	limited	to	maintain	
medullary solutes, sodium, chloride and urea, formed by the thick ascending loops of Henle 
(Brezis et al. 989, Ganong 200). 
The distal convoluted tubule is impermeable to water, although sodium and chloride are 
actively reabsorbed and potassium and hydrogen ions are secreted. The collecting ducts are only 
slightly permeable to water in the absence of ADH. When ADH is present, the collecting ducts 
are permeable to water so that water is reabsorbed and less urine is excreted (Ganong 200).
ACUTE RENAL FAILURE
There is a paucity of generally accepted diagnostic criteria for ARF. The lack of diagnostic 
consensus	makes	the	assessment	and	comparison	of	different	study	results	difficult.	Recently	
the	Conference	of	 the	Acute	Dialysis	Quality	 Initiative	group	published	 the	first	 consensus	
definitions	and	classifications	of	ARF.	These	criteria,	called	RIFLE	(Risk	of	renal	dysfunction,	






GFR criteria Urine output criteria
Risk of renal dysfunction S-crea x 50% or GFR decrease 
> 25% from baseline 
Urine output < 0.5 mL kg- h- for 
6 hours
Injury to the kidney S-crea x 200% or GFR decrease 
> 50%
Urine output < 0.5 mL kg- h- for 
2 hours
Failure of the kidney function S-crea x 00% or GFR decrease 
75% or S-crea >76 µmol L-
Urine output < 0. mL kg- h- for 
2 hours or anuria for 2 hours
Loss of kidney function Persistent ARF duration >  weeks
ESKD End stage kidney disease (>  months)
RIFLE = Risk of renal dysfunction, Injury to the kidney, Failure of the kidney function, Loss of kidney 
function	and	End	stage	renal	disease,	GFR	=	glomerular	filtration	rate,	S-crea	=	serum	creatinine,	ARF	=	
acute renal failure, ESKD = end stage kidney disease.
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On	the	basis	of	different	causal	factors	ARF	is	classified	into	three	categories:	prerenal,	renal	
or intrinsic, and postrenal. 
Prerenal ARF results from a fall in renal perfusion. Renal perfusion may decline due to hy-
povolemia and hypotension. When renal perfusion pressure decreases, GFR is controlled by 
modulating the tone in afferent and efferent arterioles. The tone in the afferent arteriole is ad-
justed by renal autoregulation, renal vasodilatory PGs and the tone in the efferent arteriole by 
angiotensin II, respectively (Brady et al. 200). Drugs interfering with renal autoregulation, e.
g. angiotensin converting-enzyme inhibitors or NSAIDs, may further decrease GFR. Usually, 
renal function returns to normal when perfusion is restored. However, acute cortical necrosis 
may ensue if poor renal perfusion persists.
Renal or intrinsic aetiology for ARF arises from various renal diseases, occlusion of renal 
vessels, ischemia, nephrotoxic agents, and diseases of renal microvascularity, glomeruli or tu-
bulointerstitial processes. Many pharmacological agents and poisons may cause acute tubular 
necrosis by inducing intrarenal vasoconstriction, direct tubular toxicity, tubular obstruction or a 
combination of these (Thadhani et al. 996). 
IMPACT OF HYPOVOLEMIA ON RENAL FUNCTION
Hypovolemia leads to a drop in the mean systemic arterial pressure, which initiates activation 
of the sympathetic nervous system and RAAS and release of ADH. Noradrenaline, angiotensin 
II and ADH act to maintain blood pressure and preserve cardiac and cerebral perfusion by caus-
ing vasoconstriction in the musculocutaneous and splanchnic circulations and inhibit salt and 
water loss. Glomerular perfusion and GFR are preserved during mild hypoperfusion through 
several compensatory mechanisms. Renal autoregulation detects reduced perfusion pressure and 
triggers afferent arteriolar vasodilatation. Intrarenal synthesis of PGs, kallikrein and kinins is 
enhanced. Angiotensin II may induce efferent arteriolar vasoconstriction and intraglomerular 
pressure is preserved and GFR is maintained (Brady et al. 200). High concentrations of 
 angiotensin II provoke vasoconstriction in both afferent and efferent arterioles (Brady et al. 
200). 
Under normal conditions, both the outer and inner medullary region of kidneys are at a low 
partial pressure of oxygen (Brezis et al. 989). Further vasoconstriction may cause ischemia in 
the metabolically active segments of the proximal tubule and the medullary thick ascending 
limb of Henle’s loop (Kopolovic et al. 989). 
In severe hypoperfusion, the renal compensatory mechanisms are overwhelmed and ARF 
may ensue. Renal autoregulation is maximal at a mean systemic arterial pressure of 80 mmHg, 
below which hypotension results in deteriorated GFR. 
2
BIOMARKERS OF RENAL FUNCTION
TRADITIONAL BIOMARKERS 
CREATININE
Creatinine (molar mass (M): ) is formed from muscular creatine and 2% of creatine is con-
verted	to	crea.	Serum	crea	reflects	GFR;	as	it	declines,	S-crea	increases	(Brady	et	al.	2004).	The	
use of S-crea as a biomarker of renal function is based on a steady state mass balance, with as-
sumptions that the rate of crea appearance in the blood stream is constant and balanced solely 
by	the	rate	of	elimination	by	filtration	through	the	glomerulus	(Brady	et	al.	2004).	However,	
crea	can	also	be	excreted	in	the	urine	by	renal	tubules,	and	a	decrease	in	glomerular	crea	filtra-
tion is compensated by an increase in crea secretion by proximal tubule cells. On the other hand, 
the rate of crea appearance into the blood stream depends on muscle mass (Grubb et al. 992).
Serum crea is routinely used to measure the perioperative renal function. The major restric-
tion for the use of S-crea is the lack of sensitivity; a 50% reduction in GFR may occur before 
S-crea levels increase (Renkin and Robinson 97, Esson and Schrier 2002), and the lack of 
specificity;	misinterpretations	may	be	caused	by	dilution	from	fluid	loading	and	muscle	mass	of	
the patients if left unnoticed. Thus, S-crea may detect an impairment in GFR in only a minority 
of patients.
CREATININE CLEARANCE
Creatinine clearance is considered a reliable measurement of GFR. Creatinine clearance meas-
ures the ability of the kidneys to clear crea from the blood into the urine over a period of time. 
A 2-hour urine collection should be used for accurate measurement, but shorter collection 
times are preferred for practical reasons. However, calculation of endogenous crea clearance 
requires a 2-hour urine sample collection, and non-compliance of patients and diseases, e.g. 
diarrhea, may adversely affect urine collection.
In clinical work the crea clearance, which is a labor-consuming technique, is not measured. 
For accurate measures non-compliant patients must be hospitalized during the urine collection 
period. Therefore, in clinical practice, glomerular function is usually estimated using calculated 
formulae.
Different formulae have been developed for estimating GFR from S-crea and biometric data. 
These formulae are based on assumptions that S-crea is constant and equal to its production, and 
that the production is proportional to muscle mass. Muscle mass is predicted from sex, age, 
weight and ethnic background. The commonly used Cockcroft-Gault formula is derived from a 
hospital population with only % of female patients (Cockcroft and Gault 976). In a validita-
tion study in a large population (n = 8592), the Cockcroft-Gault formula underestimated GFR 
and the accuracy to detect age-related renal impairment was low (Verhave et al. 200).
The	Modification	of	Diet	in	Renal	Disease	is	a	recent	formula,	based	on	data	from	a	middle-
aged population with chronic renal disease (mean S-crea 200 µmol L-) (Levey et al. 999). This 
formula is based on age, sex, race, S-crea, S-albumin and S-urea. However, this formula has not 




Urea (M: 60) is the product of amino acid metabolism. Urea is formed mainly in the liver and 
the production rate is dependent on liver function, dietary factors and nutritional status. Serum 
urea	is	filtered	in	the	glomerulus	and	reabsorbed	in	the	tubules	with	water.	When	the	urine	out-
put is high, the reabsorption decreases. The decreased GFR or urine output leads to an increase 
in S-urea. Urea measurement is used in estimating the degree of uremia and need for dialysis 
therapy.
Many extrarenal factors, e.g. augmented protein intake and protein catabolic rate, affect urea 
production. Gastrointestinal bleeding increases S-urea and some medications, e.g. the corticos-
teroids or anabolic steroids, decrease S-urea (Kellen et al. 99). 
Serum urea is as insensitive marker of GFR as S-crea. Although the changes in S-crea and 
-urea are widely used to assess postoperative renal function, they detect less than one third of 
the patients with postoperative renal deterioration (Charlson et al. 989, Kellen et al. 99).
NOVEL BIOMARKERS
CYSTATIN C
Cystatin C, a 22-amino acid cysteine protease inhibitor (M:  00), is an endogenous compo-
nent of plasma (Grubb and Löfberg 982, Grubb 992). Cystatin C is a product of a non-induc-
ible gene that is expressed in all nucleated cells, and the cystatin C protein is stable and un-
modulated (Abrahamson et al. 990). 
Cystatin	C	is	freely	filtered	by	the	glomerulus	and	it	is	neither	secreted	nor	reabsorbed	as	an	
intact	molecule	(figure	1).	S-cystatin	C	levels	better	estimate	GFR	than	S-crea	(Grubb	et	al.	
985, Swan 997). Serum cystatin C is considered especially useful in the diagnosis of mild 
renal deterioration (Bostom and Dworkin 2000). In patients with hypertension and microalbu-
minuria but otherwise normal GFR, S-cystatin C is elevated. This indicates that S-cystatin C is 
useful in detecting patients with early nephropathy with normal GFR (Coll et al. 2000).
Serum cystatin C increases when GFR decreases. Serum cystatin C can be used in clinical 
evaluation of GFR in different patient populations because it is not affected by body weight, 
diet,	medications	and	diseases	such	as	hepatic	failure,	inflammation	and	cancer	(Grubb	et	al.	
985, Demirtas et al. 200). However, glucorticoid treatment is a nonglomerular factor increas-
ing S-cystatin C, and S-cystatin C reference values in the elderly population exceed those re-
ported from adults (Wasén 200).
α-MICROGLOBULIN
α-microglobulin, also called protein HC, is a low molecular weight plasma glycoprotein (M: 
26 000– 000) (Weber and Verwiebe 992). α-microglobulin belongs to the lipocalin protein 
superfamily, and it is synthesized in the liver. In the circulation, approximately half of α-MG 
is combined with immunoglobulin A, 7% is bound to albumin and the remaining is unbound 
(Åkerström et al. 2000). α-microglobulin passes relatively freely through the glomerular mem-
brane and is reabsorbed by the proximal tubular cells which then catabolize it (Åkerström et al 
2000).
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Figure . Cortical nephron. Presented are the sites of biomarkers release in renal glomerular dysfunction 
and cellular deterioration.
 NAG = N-acetyl-β-D-glucosaminidase, S = Serum, TATI = Tumor associated trypsin inhibitor, 
U = Urine, α-MG = α-microglobulin, GST-α = Glutathione transferase-α, GST-π = Glutathione trans-
ferase-π, β2-MG = β2-microglobulin, cystatin C.
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Urine α1-MG	has	been	used	to	measure	proximal	tubular	dysfunction	(figure	1).	In	patients	
with rheumatoid arthritis, half of the patients had asymptomatic proteinuria and tubular dys-
function,	as	seen	by	increased	U-α1-MG	levels	(Niederstadt	et	al.	1999).	In	children	U-	α-MG 
excretion increases during urinary infection with pyrexia (Mantur et al. 2000). 
During surgery, U-α-MG has been used to detect early stages of tubular damage and to 
evaluate renal outcome. Decreased U-α-MG levels following renal transplantation indicates 
improved tubular function and rules out developing rejection (Teppo et al. 2000). During car-
diac surgery elevated U-α-MG indicates proximal tubular dysfunction (Gormley et al. 2000). 
N-ACETYL-β-D-GLUCOSAMINIDASE
N-acetyl-β-D-glucosaminidase, a lysosomal enzyme (M: 25 000–50 000), is released from 
the	proximal	tubular	cells	in	tubular	injury	(figure	1)	(Holdt-Lehmann	et	al.	2000). Urine NAG 
can be measured from spot samples or from a 2-hour urine collection (Wellwood et al. 975, 
Higuchi et al. 995). When spot samples are taken, U-NAG is indexed to U-crea to avoid the 
effect of different urine volumes (Wellwood et al. 975).
Urine NAG/crea is used in evaluating proximal tubular damage in different clinical settings. 
Elevated U-NAG/crea-index has been measured after cardiopulmonary bypass and kidney 
transplantation (Bornstein et al. 996, Gormley et al. 2000). Exposure to lead has been shown       
to increase U-NAG levels (Pergande et al. 99). 
β2-MICROGLOBULIN
β2-microglobulin (β2-MG) (M: 2 00), originates from the histocompatibility antigen com-
plex (Grubb et al. 985). β2-microglobulin is produced by most nucleated cells, especially 
lymphocytes (Grubb et al. 985). β2-microglobulin	 is	 filtered	 through	 the	 glomerulus	 and	
 reabsorbed in the proximal tubules. Serum and urine β2-MG increase as tubular damage 
 increases. Serum β2-MG	reflects	also	GFR	in	early	glomerular	dysfunction	(figure	1)	(Schardijn	
and Statius van Eps 987).
Serum β2-MG is used to assess renal effects of environmental and work-related cadmium 
and lead exposure (Jakubowski et al. 2002). 
There are some confounding factors to be taken in account when β2-MG is measured. Im-
munological	insults,	 including	stress	reactions	and	infections	influence	S-	β2-MG due to the 
predominant production of β2-MG in lymphocytes. Also, drugs affecting lymphocytes and their 
function, e.g. steroid therapy, may alter the β2-MG production (Honkanen et al. 995).
Diurnal variation of β2-MG production should be taken to account. In healthy patients, 
maximum S-β2-MG is measured in the morning and in patients with non-treated multiple my-
eloma, it has been observed that a peak in S-β2-MG occurs in the afternoon (Pasqualetti et al. 
99). Acidic urine, pH less than 6, causes degradation of β2-MG at body temperature and af-
fects U-β2-MG (Schardijn and Statius van Eps 987).
GLUTATHIONE–S–TRANSFERASE – α AND – π
Glutathione-S-transferases (M: 22 000–29 000) conjugate various molecules, which are detoxi-
fied	and	excreted	into	the	urine	(Harrison	et	al.	1989,	Hayes	et	al.	1991).	Glutathione-S-trans-
ferases are cytosolic enzymes present in the liver, small intestine, testis, ovaries, adrenal glands 
and kidneys (Sarvary et al. 2000).
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Glutathione-S-transferase -α and -π are considered useful tools in evaluating the site of cel-
lular	damage	in	the	kidneys	(figure	1)	(Usuda	et	al.	1999,	Branten	et	al.	2000).	Glutathione–S–
transferase-α is primarily located in the proximal tubules and GST-π is predominantly located 
in the distal tubules, collecting ducts and loops of Henle. Hence, U-GST-α is a sensitive mark-
er of proximal tubular and U-GST-π of distal tubular damage, respectively (Branten et al. 2000). 
Both biomarkers have been used to assess renal effects of F- exposure (Usuda et al. 999). 
TUMOR-ASSOCIATED TRYPSIN INHIBITOR
Tumor-associated trypsin inhibitor (M: 6 000), is expressed in the gastrointestinal, urogenital, 
and biliary tracts, in the kidney, lung, liver and breast (Stenman 2002). Tumor-associated trypsin 
inhibitor has the same structure as pancreatic trypsin inhibitor. Tumor-associated trypsin in-
hibitor	 is	filtered	 through	 the	glomerulus	and	metabolized	 in	 the	proximal	 tubule	 (Stenman	
2002). When GFR declines, S-TATI increases (Tramonti et al. 997). 
A	small	amount	of	TATI	is	excreted	in	 the	urine	of	healthy	humans,	but	significantly	 in-
creased amounts of U-TATI are measured in patients with glomerular and tubular dysfunction 
(Tramonti et al. 997).
In patients with ovarian tumors, increased S-TATI has been measured (Medl et al. 995) and 
S-TATI	may	also	be	increased	in	pelvic	inflammatory	diseases	(Paavonen	et	al.	1989).	These	
confounding factors should be taken in account when S-TATI is used to measure GFR.
PLASMA RENIN ACTIVITY
Renin is the promoter in the activation of the RAAS. Renin catalyzes the formation of 
 angiotensin I from angiotensinogen. Angiotensin I is then transformed to angiotensin II, which 
 causes vasoconstriction in renal and systemic arterioles (Ganong 200). Angiotensin II produces 
relative	cortical	 ischemia	directing	the	blood	flow	to	the	medulla	(Hall	1986).	Activation	of	
angiotensin II releases catecholamines, which cause further vasoconstriction (Giacchetti 
et al. 996). 
Impaired RBF, diminished renal perfusion pressure and decreased GFR elevates plasma 
renin activity (P-RA) (Leenen and Stricker 97). During laparoscopy, pneumoperitoneum in-
creases P-RA (Koivusalo 997). 
Plasma renin activity is a feasible method for measuring the activation of RAAS (Ganong 





fluorinated	methyl	isopropyl	ether	(Figure	2)	with	a	boiling	point	of	58.5° C and a blood-gas 
partition	coefficient	of	0.60–0.69	(Wallin	et	al.	1975).	In	adults,	the	end	tidal	minimum	alveolar	
concentration (MAC) in oxygen in air is .7–2.% and in oxygen in 60% of nitrous oxide 0.7% 
(Katoh et al. 987). 
Figure	2.	Sevoflurane.
THE METABOLISM OF SEVOFLURANE
Sevoflurane	is	mainly	removed	by	the	lungs	and	the	metabolic	rate	is	moderate	(Kharasch	et	al.	
1995a).	 Less	 than	 5%	of	 sevoflurane	 is	metabolized	 in	 the	 liver	 by	 the	CYP2E1	 to	 F- and 
	hexafluoroisopropanol	 (Kharasch	 et	 al.	 1995a).	 Intrarenal	 defluorination	 of	 sevoflurane	 is	
	minimal	(Kharasch	et	al.	1995b).	The	metabolism	of	hexafluoroisopropanol	does	not	release	
F-	and	hexafluoroisopropanol	is	secreted	into	the	urine	as	glucuronide	conjugates.
The activity of CYP 50 isoenzymes varies between individuals (Piao et al. 200). In pa-
tients with low CYP 2E activity, the increase in S-F-	is	usually	moderate	following	sevoflurane	
while in patients with high CYP 2E activity, S-F-	may	increase	significantly	after	sevoflurane	
anesthesia (Wandel et al. 997). This is a risk because high S-F-, > 50 µmol L-, is considered to 
be associated with an increased risk for renal toxicity (Cousins and Mazze 97).
COMPOUND A
Sevoflurane	 interacts	with	dry	CO2-absorbents to produce a series of degradation products: 
polyvinyl ethers, compound A, B, C, D and E (Bito and Ikeda 99, Anders 2005). Considering 
the renal effects, compound A is the most important of the degradation products. The production 
of compound A is temperature-dependent. The temperature in CO2-absorbents increases when 
low	fresh	gas	flow	is	used	or	when	CO2 production is increased (Fang et al. 995). 
In experimental studies, metabolites of compound A have caused renal proximal tubular in-
jury, but these results cannot be directly applied to humans. In rats, compound A is metabolized 
by renal cysteine β-lyases to nephrotoxic metabolites (Kharasch et al. 999). In human kidneys, 
the β-lyase pathway is less active than in rats (Kharasch et al. 999), and thus, the risk of renal 




humans. Compound A was the only detectable degradation product and the mean concentrations 
with sodalime and with baralyme were 8 and 20 parts per million, respectively (Frink et al. 
992). In Finland, sodalime absorbents are mainly used.
SEVOFLURANE ANESTHESIA AND RENAL MARKERS
N-acetyl-β-D-glucosaminidase
The renal glomerular and tubular effects of prolonged inhalation anesthesia are described in 
several studies, although the results are contradictory (table ). Higuchi and co-workers (995) 
compared	the	proximal	tubular	effects	of	9–14	MAC-hour	sevoflurane	and	isoflurane	anesthesia	
in	patients	undergoing	orthopedic	surgery.	Urine	NAG/crea	was	significantly	higher	in	those	
patients	with	sevoflurane	anesthesia	who	had	S-F- 50 µmol L- or higher when compared with 
patients	anesthetized	with	isoflurane	with	S-F- of 5 µmol L-. However, no changes in clinical 
renal function were noted (Higuchi et al. 995).
In other studies opposite results have been presented. After prolonged (6–8 MAC-hour) 
anesthesia, there were no differences in U-NAG excretion in patients anesthetized with either 
sevoflurane	or	isoflurane.	Urine	NAG/crea	increased	from	a	mean	of	5	units	g- at baseline with 
both agents to the highest concentration of 0 units g- measured at postoperative day 5 (Obata 
et al. 2000). In two other studies, no increases of U-NAG were noted after .6 and 0 MAC-
hour	sevoflurane	anesthesia	(Kharasch	et	al.	1997,	Ebert	et	al.	1998a).	In	patients	with	moder-
ately impaired renal function, crea clearance 0.7–0.92 mL s-, U-NAG did not increase from 
the	baseline	after	5	MAC-hour	sevoflurane	or	isoflurane	anesthesia	(Tsukamoto	et	al.	1996).
β2-microglobulin
Urine β2-MG has been used to evaluate the proximal tubular effect of inhalation anesthesia. 
Increased U-β2-MG	has	been	measured	after	11	MAC-hour	sevoflurane	anesthesia	(Higuchi	et	
al. 998). In a small study, U-β2-MG	increased	compared	to	the	baseline	after	sevoflurane	in-
halation,	but	repeated	sevoflurane	anesthesia	did	not	affect	U-β2-MG (Nishiyama et al. 998).
Patients with moderately impaired renal function, crea clearance 0.7–0.92 mL s-, and 
chronic	renal	failure	receiving	hemodialysis	were	anesthetized	with	5	MAC-hour	sevoflurane	
without	any	significant	changes	in	U-β2-MG (Nishiyama et al. 996, Tsukamoto et al. 996).
Glutathione	transferase-α	and	-π
Urine GST-α and- π	have	been	used	to	detect	possible	renal	tubular	damage	after	sevoflurane	
anesthesia	with	controversial	 results.	 In	one	study,	10	MAC-hour	sevoflurane	anesthesia	re-
sulted in increased U-GST-α and- π with albuminuria and glucosuria for one to three days after 
anesthesia	(Eger	et	al.	1997).	These	findings	have	not	been	confirmed	by	others.	After	10	MAC-
hour	sevoflurane	anesthesia,	using	a	similar	study	setting,	the	U-GST-α and -π excretion was 
slightly elevated at 8 hours after anesthesia but both biomarkers returned to normal at 72 hours 
without	significant	glucosuria	or	albuminuria	(Ebert	et	al.	1998a).	In	another	trial,	there	were	no	





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Enflurane	(M=185)	is	a	volatile	liquid	anesthetic	(Figure	3)	with	a	boiling	point	of	56.5° C and 
a	blood-gas	partition	coefficient	of	1.9.	The	enflurane's	MAC	in	oxygen	in	air	 is	1.7%	(end	
tidal concentration) and in oxygen in 70% nitrous oxide 0.6% (Gion and Saidman 97). 
METABOLISM OF ENFLURANE
2%	of	enflurane	is	metabolized,	predominantly	in	the	liver	by	CYP2E1,	to	F- (Kharasch et al. 
99). In healthy volunteers, the renal concentrating capacity decreases with S-F- of  µmol 
L-	after	enflurane	anesthesia	(Mazze	et	al.	1977).	Reactive	intermediate	metabolic	products	
may	also	be	potentially	nephrotoxic.	Alkaline	degradation	of	enflurane	produces	halogenated	
alkenes that are conjugated further to possibly nephrotoxic thiol compounds (Orhan et al. 200). 
Fluoride is excreted in the urine and high U-pH increases F- clearance (Oikkonen 98), de-
creasing possible renal toxicity.
INORGANIC FLUORIDE FORMED IN THE METABOLISM OF 
ENFLURANE AND SEVOFLURANE AND RENAL FUNCTION 
Fluorine substitution can alter the chemical properties, metabolism, disposition (distribution of 
the drug, drug clearance and routes of clearance) and biological activity of drugs (Park et al. 
2001).	Fluorine	forms	a	strong	bond	with	carbon	in	flurane-type	inhalation	anesthetics.	Fluorine	
may increase lipophilicity of an inhalation anesthetic and passive diffusion across membranes 
and facilitating penetration to the central nervous system. Fluoride substitution may alter the 
metabolism and toxicity of the drug. This can be noted in the development of modern inhalation 
anesthetics. Extensive release of F-	 in	 the	metabolism	of	methoxyflurane	caused	high	urine	
output	syndrome	and	even	fatal	renal	failure.	By	increasing	fluorine	substitution,	as	in	enflurane	
and	isoflurane,	a	reduction	of	metabolism	and	defluorination	can	be	achieved	(Park	et	al.	2001).	
The	metabolism	of	sevoflurane	produces	relatively	high	S-F-, but severe renal failure has not 




energy production. The adenosine triphosphatase enzyme and membrane transport is impaired 
(Oikkonen 98). Fluoride toxicity causes ADH resistant polyuria, so it may be assumed that 
the F- dissipates the concentration gradient in the renal medulla inhibiting sodium and chloride 
reabsorption into the ascending loop of Henle. Also, the ADH mediated water reabsorption in 
the collecting duct is inhibited (Rush and Willis 982). Fluoride induces inhibition of salt and 
water reabsorption in the proximal tubule (Mazze 976). In acidic milieu, hydrogen F (weak 
acid	pKa	3.3)	is	mostly	nonionized	and	is	easily	absorbed	into	tubular	cells	to	be	filtered	again	
in the glomerulus, which increases the potential for renal toxicity. If urine pH is increased, a 
greater fraction of F is ionized and is excreted into the urine, hence, becoming harmless (Järn-
berg et al 98).
NONSTEROIDAL ANTI-INFLAMMATORY  
ANALGESIC DRUGS
The mechanism of action of NSAIDs is based on their ability to reduce the formation of PGs 
(Vane 97). This ability is associated with inhibition of the cyclo-oxygenase (COX) enzyme, 
which converts arachidonic acid to different prostanoids. The prostanoid family includes PGD2, 
PGE2, PGF2α, prostacyclin (called also PGI2), and thromboxane A2. The COX enzymes exist in 
at least two isoforms, COX- and COX-2 (Vane 99). Cyclo-oxygenase- is constitutively 
expressed and responsible of production of physiologically important prostanoids. Cyclo-oxy-
genase	-2	is	rapidly	up-regulated	by	inflammatory	stimuli.	Cyclo-oxygenase-2	is	also	constitu-
tively expressed in the central nervous system, reproductive organs, and kidneys, and has phys-
iological	 roles	 such	as	maintaining	 the	fluid	balance	 in	 the	kidneys	 (Kammerl	 et	 al.	 2001).	
Recently, a variant of COX- has been detected in the brain and named COX-. Some of the 
therapeutic actions of paracetamol are supposed to be mediated by COX – (Chandrasekharan 
et al. 2002).
Conventional NSAIDs prevent the function of both COX- and -2 isoforms and the COX- 
sparing NSAIDs (coxibs) inhibit COX-2 at lower concentrations than COX-. NSAIDs are 
widely used to treat mild postoperative pain after minor surgery (Nikanne et al. 999), and in 
adjunct to opioids and other pain relieving modalities for moderate to severe pain after major 
surgery (Kokki et al. 999). Many NSAIDs are also available in a parenteral form which may 
facilitate perioperative administration.
NSAIDS AND RENAL FUNCTION 
In non-surgical hospitalized patients with NSAIDs, the incidence of ARF varies from  to % 
(Feldman et al. 997, Whelton 2000). In high-risk patients with PG dependent renal function 
(e.g. patients with hypovolemia, heart failure, liver cirrhosis or underlying renal disease), 
NSAIDs reduce RBF and GFR in a dose-dependent fashion and ARF may ensue (Delmas 995). 
Also, patients using angiotensin converting enzyme inhibitors or angiotensin receptor agonists 
in combination with NSAIDs are at risk of renal deterioration. Many mechanisms are included, 

with inhibition of PG dependent vasodilatation of the afferent arteriole and angiotensin-medi-
ated vasoconstriction of the efferent arteriole being the most important (Juhlin et al. 200, Lo-
boz	and	Shenfield	2005).	
Kidneys produce PGE2 and PGI2. In normal situations, PGs may have only a minor role in 
maintaining renal function, but in patients with hypovolemia, catecholamines induce production 
of renal PGs, which vasodilate the afferent renal vessels, thus preserving RBF and function 
(Yared et al. 985). If the PG synthesis is prevented by NSAIDs in hypovolemic patients, 
 angiotensin II, ADH and catecholamines may cause vasoconstriction in renal vessels, and RBF 
and GFR are declined. If vasoconstriction of afferent vessels is maintained, renal failure may 
eventually ensue.
In patients with perioperative NSAIDs, minor changes in renal function are common and 
some	degree	of	fluid	and	sodium	retention	occurs	in	nearly	all	patients	(Lee	et	al.	2004).	More	
serious complications may also occur with long-term NSAID use. Hyperkalemia, reversible 
nephrotic syndrome with interstitial nephritis, permanent papillary necrosis and interstitial scar-
ring are reported in patients on a long-term NSAID regimen (Whelton and Hamilton 99, 
Rocha et al. 200). Other structural changes caused by NSAIDs are tubular necrosis and renal 
interstitial	infiltration	of	lymphocytes	(Kleinknecht	et	al.	1986).	
The incidence of NSAID-related renal structural alterations appears to be low, although the 
true	number	of	patients	may	be	significant	considering	the	wide	use	of	NSAIDs.	According	the	
Royal College of Anaesthetists guidelines (998), renal function should be monitored regularly 
in at risk patients undergoing major surgery when NSAIDs are administered during the periop-
erative period.
KETOROLAC 
Ketorolac (M=76), a pyrroleacetic acid derivative (Figure ), is a nonselective NSAID that has 
been marketed in Finland since 99. Ketorolac is available as a parenteral form, which enables 
the perioperative i.v. (intravenous) and i.m. (intramuscular) use. When injected intramuscularly, 
the peak concentration of ketorolac occurs 50 minutes after injection, and the elimination half-
life in healthy persons is 5 hours. The analgesic effect of ketorolac is noted 0 minutes post-
injection (Maunuksela et al. 992). Ketorolac is eliminated by glucuronidisation in the liver and 
excreted by the kidneys. The metabolites have no analgesic effect (Gillis and Brogden 997).
Figure . Ketorolac.
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Ketorolac is used to treat moderate and severe postoperative pain. Ketorolac is effective in 
treating pain after laparoscopic surgery (Lane et al. 996) and laparotomy (Barton et al. 2002). 
After hip replacement, ketorolac was as effective as diclofenac and ketoprofen (Kostamovaara 
et al. 998).
Ketorolac may cause adverse reactions typical for NSAIDs. After major surgery, periopera-
tive bleeding from the surgical site and gastrointestinal tract, allergic reactions and ARF are 
reported with the same incidence in patients receiving ketorolac, ketoprofen or diclofenac (For-
rest et al. 2002). After major surgery, renal impairment is detected in 0.% of patients receiving 
ketorolac, ketoprofen or diclofenac (Forrest et al. 2002). According to the marketing authoriza-
tion holder, the maximum recommended daily dose of ketorolac is 20 mg, and the administra-
tion	should	not	exceed	two	days.	The	use	of	ketorolac	for	more	than	five	days	may	be	associ-
ated with increased incidence of ARF (Feldman et al. 997).
CLONIDINE
Clonidine (M=267), a 2-imidazoline derivative, is an adrenoreceptor agonist (Figure 5). Cloni-
dine	has	a	greater	affinity	to	presynaptic	α2-adrenergic receptors than postsynaptic α-recep-
tors, the α2/α-selectivity ratio of 220 (Virtanen et al. 988). 
The bioavailability of oral clonidine is 75% and the elimination half-life of clonidine varies 
between 0–20 hours. Half of clonidine is eliminated unchanged, mainly by the kidneys, and 
20% of clonidine is secreted into the feces (Lowenthal 980).
Clonidine acts centrally, at the medulla oblongata, and peripherally. Clonidine reduces sym-
pathetic tone. Consequently, peripheral vascular resistance decreases resulting in a fall in diasto-
lic and systolic blood pressure and a reduction in heart rate (Kallio et al. 990). The dose re-
sponse of clonidine on blood pressure follows a U-shaped curve. Low doses of clonidine (2 µg 
kg- or less) do not affect blood pressure and high doses (6 µg kg- or more) with peripheral 
vasoconstriction from high circulating drug concentrations oppose central sympatholysis 
 (Eisenach et al. 996).
Clonidine decreases cardiac output. This effect is based on decreased heart rate, as stroke 
volume is not affected (Kallio et al. 990). However, during CO2 pneumoperitoneum high dose 
of clonidine, 8 µg kg-, does not affect cardiac output in normovolemic patients (Joris et al. 
998).
Figure 5. Clonidine hydrochloride.
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CLONIDINE AND RENAL FUNCTION
In	the	kidney,	clonidine	inhibits	fluid	reabsorption	in	the	proximal	tubules	(Rouse	et	al.	1990)	
and subsequently increases sodium and water excretion (Gellai and Ruffolo 987). Kulka and 
co-workers (996) demonstrated that clonidine maintains renal function after cardiac surgery. 
Although clonidine decreases cardiac output, it does not decrease GFR and RBF (Barendregt et 
al. 99). 
The renal effect of clonidine may be based on decreased vasoactive hormones that affect 
renal vasoconstriction. The effect of ADH on renal collecting tubules is inhibited by clonidine 
(Gellai and Edwards 988). Clonidine also inhibits the central ADH secretion (Peskind et al. 
1987),	but	conflicting	results	exist	(Pouttu	et	al.	1987).	During	isoflurane	anesthesia,	ADH	se-
cretion was similar but mean urine output was doubled in the patients receiving clonidine (5 µg 
kg-), as compared with the control patients (Hamaya et al. 99). 
Clonidine (8 µg kg-) reduces the release of noradrenaline during laparoscopy (Joris et al. 
998). During major vascular surgery, serum concentrations of adrenaline, noradrenaline and 
ADH are low in patients receiving clonidine (7 µg kg-) (Quintin et al. 99).
CIRCULATORY EFFECTS OF CARBON DIOXIDE 
PNEUMOPERITONEUM
Due to its physical safety, CO2 is used for creation of pneumoperitoneum in laparoscopic sur-
gery. Carbon dioxide is a normal product of human metabolism and it is non-toxic in physiol-
ogical concentrations (Lenfant and Aucut 965). However, CO2 has direct and indirect hemody-
namic effects. Carbon dioxide dilates peripheral arterioles and depresses myocardial 
contractility. Indirectly CO2 activates the central nervous system and evokes sympathoadrenal 
responses causing tachycardia (Cullen and Eger 97). Carbon dioxide pneumoperitoneum in-
creases arterial blood pressure and peripheral vascular resistance and reduces cardiac output 
(Hirvonen	et	al.	1997).	In	patients	without	fluid	preloading,	stroke	volume	and	cardiac	output	
decrease after head up tilt and CO2-insufflation.	These	changes	resolve	after	laparoscopy	(Joris	
et al. 998). On the contrary, in healthy patients (Andersson et al. 200) or patients with ap-
propriate hydration therapy prior to the pneumoperitoneum, cardiac output increases after CO2-
insufflation	(Bäcklund	et	al.	1998).	
CARBON DIOXIDE PNEUMOPERITONEUM AND RENAL FUNCTION
In normal conditions the abdominal cavity is pressureless. In experimental studies where renal 
vein pressure was increased by mechanical compression of renal vessels, RBF and GFR de-
creased (McDougall et al. 996, Doty et al. 2000). When the abdominal cavity is pressurized to 
an intra-abdominal pressure (IAP) of 5 mmHg, which is higher than the normally suggested 
maximum of 2 mmHg, the renal vascular resistance increases and RBF and GFR decrease 
(Chiu et al. 995). During laparoscopy, the harmful effects of the compression of renal vessels 
by pneumoperitoneum on renal function are enhanced by the simultaneous neuroendo-
7
crinological changes induced by surgical stress such as increased P-RA and catecholamine 
 release (Koivusalo 997). 
Urine output decreases during laparoscopic surgery, but recovers after pneumoperitoneum 
(Chiu et al. 995, Koivusalo 997). The reason of impaired urine output is multifactorial and 
not fully understood (Koivusalo 997). The release of vasoactive substances during pneumoper-
itoneum may contribute also to decreased urine output. Adrenaline, noradrenaline and ADH are 
increased during pneumoperitoneum (Viinamäki and Punnonen 982, Koivusalo 997, Joris et 
al. 998). Vasoconstriction induced by the catecholamines and the effect of ADH are other rea-
sons for decreased urine output during laparoscopy.
SMOKING AND FLUORIDE RELEASE FROM ENFLURANE 
AND SEVOFLURANE 
Smoking is common in Finland and it is reported that 5–20% of Finnish women smoke ciga-
rettes regularly (Uutela and Koskinen 2002). Tobacco smoke consists of numerous components, 
some of which have been investigated regarding their pharmacological effects on the body 
(Miller 990). Tobacco smoke may also interact with drugs and potentially alter their pharma-
cokinetic and pharmacodynamic properties (Zevin and Benowitz 999). 
Tobacco smoke may both inhibit and induce drug metabolism. Nicotine and its main me-
tabolite cotine inhibit CYP 2EI in the liver (Van Vleet 200). CYP 2E is the isoenzyme respon-
sible	for	defluorination	of	fluorinated	ether	anesthetics	(Kharasch	and	Thummel	1993,	Kharasch	
et al. 99) and increased CYP 2E activity may increase inhalation anesthetic metabolism and 
result in a quicker and smoother recovery from anesthesia (Sweeney 200). The CYP 2E en-
zyme metabolizes ethanol and paracetamol although smoking does not inhibit their metabolism 
(Zevin and Benowitz 999). 
On the other hand, nicotine induces several microsomal enzymes such as CYP 2A/2A2 and 
CYP 2B/2B2 (Zevin and Benowitz 999). Induction of liver enzymes in smokers increases the 
metabolism of numerous drugs (Vähäkangas et al. 98, Miller 990). Tobacco smoke consists 
of polycyclic aromatic hydrocarbons, which are formed as a result of incomplete combustion of 
organic materials (Miller 990). Polycyclic hydrocarbons, e.g. anthracine and benzopyrene, are 
also potent inducers of drug metabolism (Jusko 979). 
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AIMS OF THE STUDY
The aim of the present study was to assess renal function and cellular integrity during and after 
anesthesia and surgery using sensitive biomarkers of glomerular function, tubular function and 
cellular damage. Special emphasis was placed on determining whether F- derived from the me-
tabolism	of	enflurane	and	sevoflurane,	as	well	as	whether	concomitant	use	of	ketorolac	or	clo-
nidine with inhalation anesthesia would result in changes in renal function or cellular damage. 
Sensitive biomarkers were used in order to also detect minor deteriorations.
The	specific	aims	of	the	present	study	were:
. To assess the effects of perioperative ketorolac on renal function and cellular integrity (Study 
).
2. To assess the effects of F-	on	renal	function	and	cellular	integrity	after	enflurane	and	sevo-
flurane	anesthesia	(Study	3,	4).
. To assess the effects of cigarette smoking on production of F-	in	patients	with	enflurane	and	
sevoflurane	anesthesia	(Study	3,	4).	
. To assess the effects of preoperative clonidine on renal function and cellular integrity during 




The study was carried out in Surgical Hospital and Women’s Hospital in Helsinki University 
Hospital and in Kuopio University Hospital. A total of  patients with ASA (American Soci-
ety of Anesthesiologists) physical status I–II (American Society of Anesthesiologists 2006) 
undergoing conventional or endoscopic surgery were included. Written informed consent was 
obtained from each patient. The study protocols were accepted by the ethics committees of the 
hospitals. The studies were conducted according to good clinical practice guidelines (European 
Agency for the Evaluation of Medicinal Products 2005) and Declaration of Helsinki (World 
Medical Association 200). In studies –2, patients were randomly allocated to one of two 
study groups. In studies –, two parallel cohorts of women, non-smokers and smokers, were 
compared (table ). None of the enrolled patients was excluded.
Table . The characteristics of the studies –.
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The exclusion criteria were allergy or other contraindications for drugs used, obesity (body 
mass index over 2 kg m-2), pre-existing renal and/or hepatic diseases, recent use of NSAIDs 
(study ), use of angiotensin converting enzyme inhibitors and angiotensin receptor antagonists 
(study 2), and concomitant medication known to affect CYP50 activity (study –5).
The blood and urine biomarkers of renal function and integrity as well as the collection times 
for each of the four studies are listed in table . 
2
Study 1, publication I: Thirty women, aged 28–60 years, were given three i.m. doses of 
either ketorolac 0 mg or normal saline as placebo 60 minutes prior to, at the end of and six 
hours	after	sevoflurane	anesthesia	(table	3).	
Blood and urine samples for the analyses of S- and U-F- and U-crea were collected at base-
line,	at	2	hours	of	the	anesthesia,	and	at	2,	12,	24	and	48	hours	after	the	end	of	sevoflurane	in-
halation. Blood hemoglobin and hematocrit were measured at baseline and at 2 hours after the 
anesthesia. Urine samples for the analyses of renal biomarkers were collected at timepoints 
shown in the table . Urine α-MG is a marker of proximal tubular function and U-NAG of 
proximal tubular cellular deterioration.
Study 1, publication II: In the second publication of the study  additional renal glomerular 
and tubular biomarker concentrations were reported (table ). Urine GST-α and -π are biomar-
kers of proximal and distal tubular cellular deterioration, respectively.
For 0 patients from each group S-cystatin C, a biomarker of GFR, was measured at baseline 
and at 8 hours after the anesthesia (table ). 
Study 2, publication III: Thirty patients, 2 women and 9 men aged 27–59 years, were 
given clonidine .5 µg kg- or normal saline as a placebo i.m. 60 minutes before anesthesia 
(table ). 
Blood and urine samples for assessment of U-crea were collected at baseline, at 5, 0, 60 
minutes after the induction of pneumoperitoneum, and at , , and 2 hours after the pneu-
moperitoneum. Urine NAG, biomarker of proximal tubular deterioration, S-ADH and P-RA 
were sampled at timepoints shown in the table . 




Blood samples for S-F- were collected at baseline and at , 2, , 6, 2 and 2 hours after the 
anesthetic inhalation. Serum for S-crea was collected at baseline, and at 2 and 8 hours after 
the anesthesia. Serum TATI and β2-MG, biomarkers of glomerular function, and U-TATI and 
U-β2-MG, biomarkers of proximal tubular deterioration, were sampled at timepoints shown in 
table . 
Study 4, publication V: The	study	protocol	was	similar	to	study	3,	but	instead	of	enflurane,	




























































































































































































































































































































































































































































































































Anesthesia was standardized in each study. Diazepam 5–0 mg was given for premedication by 
mouth 60 minutes before anesthesia. Glycopyrrolate (0.2 mg, study , or 0. µg kg-, study 2) 
and fentanyl or alfentanil was administered i.v. (study 2). Propofol (2– mg kg-) i.v. was used 
for anesthesia induction. Tracheal intubation was facilitated with cis-atracurium (study  and 2) 




Fluid therapy was standardized. In study , Ringer’s acetate and 6% hydroxyethyl starch 
infusion were used to maintain central venous pressure at 6–2 mmHg. In study 2, patients were 
hydrated with Ringer’s acetate infusion (8 mL kg-) i.v. for 20 minutes followed by an addi-
tional infusion (0 mL kg- h-) and 500 mL of 6% hydroxyethyl starch. In studies  and , 
Ringers’ acetate infusion was given (0 mL kg-) at the induction of anesthesia and followed by 
an infusion (5 mL kg- h-)	during	surgery	and	recovery	room	stay.	From	the	first	postoperative	
day all patients were allowed to drink freely.
ANALYTICAL METHODS
The concentrations of F-	were	determined	by	a	method	modified	from	that	of	Fry	and	Taves	
(1970).	A	fluoride	selective	combination	electrode	was	used	for	the	measurement.	The	sensitiv-
ity of the assay was 0.5 µmol L-	and	the	interassay	coefficient	of	variation	was	less	than	8%.	
The activity of U-NAG was determined by using -cresonsulphonphtalein-N-acetyl-β-
 glucosamine as a substrate (Boehringer Mannheim Biochemica, Mannheim, Germany) (Noto 
et al. 98). The activity of NAG was normalized to U-crea and expressed as U-NAG/crea 
(units of U-NAG activity per gram or mmol of U-crea) (Wellwood et al. 975).
Serum and urine β2-MG	samples	were	analyzed	using	time-resolved	fluoroimmunoassay	
with	dissociation	enhanced	lanthanide	fluoroimmunoassay	β2- microkit®	(Delfia® Wallac Oy, 
Turku, Finland). The analyses of S- and U-sodium, -potassium and -crea as well as S- and U-
osmolality and S-urea were performed in the laboratory of clinical chemistry of the Helsinki 
University Hospital (Hospital District of Helsinki and Uusimaa, Huslab 2005) or Laboratory 
Centre, Kuopio University Hospital (Kuopio University Hospital, Laboratory Centre 2005).
Serum cystatin C was determined using a DAKO Cystatin C PET kit (Dako Inc., Copenha-
gen Denmark) at United Laboratories Ltd., Helsinki, Finland. Urine α-MG was analyzed by 
radioimmunoassay according the method described by Teppo and co-workers (2000). Urine 
GST-α was analyzed by enzyme immunoassay using Nephkit-Alpha, and U-GST-π using 
Biotrin Nephkit-Pi (Biotrin International Ltd., Sinsheim-Reihen, Germany). To eliminate the 
influence	of	variations	 in	urine	volume,	α-MG, GST-α and -π were normalized to U-crea 
taken	from	spot	samples.	Urine	crea	was	measured	by	the	modified	Jaffe	reaction	(Junge	et	al.	
200, Hospital District of Helsinki and Uusimaa, Huslab 2005), and S-and U-phosphate were 
measured by a photometric method (Anner and Mossmayer 975). 
The reference value for S-cystatin C < .2 mg L- in adults aged 50 years or less and < . 
mg L- in adults older than 50 years. The reference values for S-crea is 60–00 µmol L- for men 
and 50–90 µmol L- for women and for S-urea, .5–8. mmol L- for men and .–7.9 mmol 
5
L- for women (Hospital district of Helsinki and Uusimaa 2005). The reference values for U-
α-MG/crea are 0.27 (0.0–0.70) g mol- (mean and minimum-maximum), U-GST-α/crea 0.6 
(0.0–.9) and U-GST-π/crea 2. (0.25–7.) mg mol-. Reference values for U-α-MG/crea 
were derived from  healthy individuals (2–6 years) (Teppo et al. 2000) and U-GST-α/crea 
and -π/crea from 8 adult men age of 8–6 years (Teppo A-M, personal communication 2000). 
The reference values obtained from  healthy men and 5 women for uncorrelated U-NAG is 
0.65–6. units L- (Koivusalo 997). 
Plasma RA and S-ADH were analyzed by radioimmunoassay (Fyhrquist et al. 976).
Serum and U-TATI were analyzed by radioimmunoassay (Orion Diagnostica, Espoo, Fin-
land). The reference values for S-TATI are 0–2 nmol L- (pathological if >  nmol L-), for U-
TATI indexed to U-crea 0–0.6 0–6, and for S-β2-MG 0.6–.0 mg L- and for U-β2-MG less 
than 0.25 mg L-, respectively (Hospital district of Helsinki and Uusimaa 2005, Kuopio Univer-
sity Hospital, Laboratory Centre 2005).
STATISTICAL ANALYSIS
Parametric tests were used for variables with normal distribution and nonparametric tests for 
variables with skewed distributions. The Friedman test was used to compare S-F- and urine 
marker concentrations observed over the different sample times and Wilcoxon signed ranks test 
for pair-wise comparisons (study –). For differences between the groups concerning continu-
ous data, the unpaired t-test and Mann-Whitney U-test were used. For categorical variables, the 
chi	squared-test	was	used.	Correlations	were	calculated	using	the	Pearson	correlation	coeffi-
cient.	A	p-value	of	0.05	or	less	was	considered	statistically	significant.	
In the original publications (I–III) parametric tests were used, but because the distribution of 
the data was skewed, the statistics for studies  and 2 were recalculated using nonparametric 
tests.
The statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS version .5, SPSS Inc., Chicago, USA).
6
RESULTS
The total number of patients was . The patient characteristics and the type of surgery are 
presented	 in	 tables	 5	 and	 6.	The	 anesthesia	 and	 fluid	 therapy	were	 standardized	 and	 these	
 protocols were used without any major deviations considered to affect the study parameters. 













12/3 3 12/3 Mastectomy 4





8/7 7 12/3 Mastectomy 5









































0/25 23 19/6 Laparotomy 13
Laparoscopy 10
Vaginal 2
ASA = American Society of Anesthesiologists physical status, na = not available. 
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GLOMERULAR FUNCTION
SERUM CREATININE AND UREA
None of the  patients (studies –) developed acute renal deterioration, seen as increased 
S-crea or S-urea (table 7). The median of baseline S-crea was 7 (range 7–99) µmol L- and it 
decreased to 69 (7–95) µmol L- at 2 hours after the anesthesia (p = 0.00, Wilcoxon signed 
ranks test). The highest S-crea, 99 µmol L-, was measured from a 2-year old man in the clo-
nidine study (study 2).
The median of baseline S-urea was .2 (2.–7.9) mmol L- and it decreased to . (.6–6.6) 
mmol L- at 2 hours after the anesthesia (p = 0.00,Wilcoxon signed ranks test). The highest 
S-urea, 7.9 mmol L-, was measured from a 59-year old man in the clonidine study (study 2).










































































































* p = 0.00 (Mann Whitney U-test) between the two study groups. Fluid therapy = Fluids administered 
during anesthesia and 2 hours after anesthesia, MAC = Minimum alveolar concentration, crea = creatinine, 






Ketorolac study (study 1)




were no differences in S-cystatin C between the patients with ketorolac and controls (p = 0.5). 
At baseline in the control patients, the median of S-cystatin C was 0.8 (0.6–0.9) mg L- and at 
8 hours after the anesthesia 0.8 (0.5–0.9) mg L- (p = 0.2) and in the patients with ketorolac 
at baseline 0.8 (0.6–0.9) mg L- and at 8 hours 0.7 (0.5–0.8) mg L- (p = 0.66), respectively 
(table 7). 







































































































na na na na
na = not available, crea = creatinine, S = serum
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SERUM AND URINE TATI
Enflurane	study	(study	3)
In studies  and , S- and U-TATI were used to assess the renal glomerular function.
Serum	TATI	did	not	change	after	one	MAC-hour	enflurane	inhalation,	and	there	were	no	
differences in S-TATI between the two study groups (p = 0.2). In the non-smokers, the median 
of S-TATI at baseline was .0 (0.5–.6) nmol L- and at 2 hours .0 (0.5–2.8) nmol L- (p = 
0.5), and in the smokers at baseline . (0.5–5.2) nmol L- and at 2 hours . (0.5–5.8) nmol 
L- (p = .0). At baseline S-TATI was over  nmol L-	in	2/17	smokers.	After	the	enflurane	an-
esthesia, S-TATI increased over 2 nmol L- in one patient and over  nmol L- in two patients in 
both study groups. The patients with high S-TATI did not have any higher S-F-, median  
(range –2) µmol L-, than those with S-TATI within the reference values, S-F- 6 (8.–8) 
µmol L- (p = 0.8).
There	were	no	differences	in	U-TATI	at	baseline	or	after	one	MAC-hour	enflurane	anesthesia	
between the two study groups (p = 0.8). However, U-TATI increased both in the non-smokers, 
the median of U-TATI/crea 0. (0.–.) 0–6 at baseline to 0.5 (0.–2.7) 0–6 at 2 hours after 
the anesthesia (p = 0.02, Wilcoxon signed ranks test), and in the smokers U-TATI/crea 0.6 
(0.–5.) 0–6 at baseline increased to 0.7 (0.2–7.) 0–6 at 2 hours (p = 0.009). At 8 hours the 
median of U-TATI/crea decreased to baseline both in the non-smoking patients, 0.6 (0.–.) 
0–6 and in smoking patients, 0.5 (0.–.6) 0–6. At baseline U-TATI/crea was over 0.6 0–6 in 
/6 non-smoking and in 5/7 smoking patients. At 2 hours U-TATI/crea increased to over 
0.6 0–6 in /6 non-smokers and in 5/7 smokers (p=0.085).
Sevoflurane	study	(study	4)
In	 study	 4,	 S-TATI	 increased	 after	 sevoflurane	 anesthesia	 in	 both	 the	 non-smokers	 and	 the	
smokers and there were no differences in S-TATI between the two study groups at baseline or 
at	24	hours	after	the	sevoflurane	inhalation	(p	=	0.31).	In	the	non-smokers,	the	median	of	S-
TATI . (0.5–2.) nmol L- at baseline increased to . (0.5–.) nmol L- at 2 hours after the 
anesthesia (p = 0.0, Wilcoxon signed ranks test). In the smokers, S-TATI . (0.5–2.6) nmol 
L- at baseline increased to .6 (0.5–8) nmol L- at 2 hours after the anesthesia (p = 0.005). 
S-TATI increased above the upper concentration of normal of 2 nmol L- in 5/25 non-smok-
ers	and	in	12/25	smokers	(p	=	0.035,	chi	square	test)	after	one	MAC-hour	sevoflurane	anesthe-
sia. Serum TATI increased above the pathological concentration of .0 nmol L- in  women, 
(four non-smokers and seven smokers, p = 0.). In a post-hoc analysis it was revealed that in all 
five	women	(one	non-smoker	and	four	smokers)	with	S-F- over 0 µmol L- and the 2 hour area 
under S-F- concentration time curve (AUCF0-2) over 500 µmol h L- S-TATI increased over .0 
nmol L-. On the contrary, among the 5 women with the maximum S-F- less than 0 µmol L-, 
only six had S-TATI over .0 nmol L- (p = 0.00).
In four women, one non-smoker and three smokers, with both increased S-TATI (≥ .0 nmol 
L-) and S-F- (≥ 0 µmol L-) U-TATI/crea increased over 0.6 0–6. Confounding factors to be 




Ketorolac study (study 1)
The effect of ketorolac on renal glomerular function was evaluated with S-β2-MG in patients 
with	a	3.3	MAC-hour	sevoflurane	anesthesia.	
In that study, S-β2-MG remained at low concentrations. Even the highest S-β2-MG meas-
ured, .9 mg L- from a control patient at 8 hours after the anesthesia, S-β2-MG was within the 
reference limits of 0.6–.0 mg L- (Hospital district of Helsinki and Uusimaa, Huslab 2005).
Enflurane	(study	3)	and	sevoflurane	study	(study	4)
In study  and study  the effects of S-F- on glomerular function were evaluated in the non-
smokers	and	the	smokers	undergoing	gynecological	surgery	with	one	MAC-hour	enflurane	or	
sevoflurane	anesthesia.




evaluated with U-α-MG/crea-ratio. The effect of inhalation anesthesia on cellular integrity of 
proximal tubules was evaluated in the non-smoking and smoking patients, and in the patients 
with ketorolac and with clonidine using U-NAG/crea (study , 2), U-β2-MG (study , , ), and 
U-GST-α/crea-ratio (study ). The results of tubular function and cellular damage biomarkers 
that are not correlated to U-crea are presented in tables 8 and 9 (studies , 2).
URINE α-MICROGLOBULIN
Ketorolac study (study 1)
In study , U-α-MG/crea was not a reliable indicator of the proximal tubular dysfunction. In 
this population U-α-MG/crea was > 0.7 g mol- (the highest ratio measured from healthy vol-
unteers, Teppo et al. 2000) already at baseline in /5 controls and in 2/5 patients with ketoro-
lac (p = 0.65). 
In the controls, U-α-MG/crea increased to its highest at 8 hours (p = 0.06). In the control 
patients U-α-MG/crea, .2 (0.–.) g mol-,	at	48	hours,	was	significantly	higher	than	that	in	
the patients with ketorolac, 0. (0.–.) g mol-, (mean difference 0.6 g mol-,	95%	confidence	
interval (CI) for difference: 0.0 to .2 g mol-, p = 0.02, Mann Whitney U-test) (Figure 6). In 
all patients except one with ketorolac U-α-MG/crea was higher than > 0.7 g mol- at some state 
of surgery or the 8 hours recovery period, and at 8 hours /5 controls and 5/5 with ketoro-
lac still had U-α-MG/crea > 0.7 g mol- (p = 0.028).
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URINE N-ACETYL-β-D-GLUCOSAMINIDASE 
Ketorolac study (study 1)
In study , an increase in U-NAG/crea, a marker of proximal tubular deterioration, was noted 
in both the controls and the patients with ketorolac undergoing breast surgery with a . MAC-
hour	sevoflurane	anesthesia	(p	=	0.001	Friedman	test).	In	the	controls,	the	median	of	U-NAG/
crea increased from . (0.2–2) units g- at baseline to .5 (0.7–) units g- at two hours of 
anesthesia and in the patients with ketorolac the median of U-NAG/crea increased from . 
(0.5–.8) units g- at baseline to .0 (.5–7) units g- at two hours in anesthesia, (p = 0.05, 
Wilcoxon signed ranks test). Urine NAG/crea returned to the baseline at 2 hours after the an-
esthesia in both groups.
At baseline the uncorrelated U-NAG was over 6. units L- (above the highest concentration 
measured from healthy volunteers) in one control and in one patient with ketorolac. During or 
within	2	hours	after	the	sevoflurane	anesthesia,	U-NAG	increase	to	over	6.1	units	L- in 5/5 
patients with ketorolac, but in none of the controls (p = 0.02, Fisher’s exact test) (table 8).
Clonidine study (study 2)
Patients with clonidine developed a minor and transient increase in U-NAG/crea during pneu-
moperitoneum. Urine NAG/crea increased to its highest level at 60 minutes of pneumoperito-
neum both in the controls and in the patients with clonidine (p = 0.00, Wilcoxon signed ranks 
test). In the control patients, the median of U-NAG/crea 0. (0.2–0.5) units g- at baseline in-
creased to 0.7 (0.–.7) units g- at 60 minutes of pneumoperitoneum, and in the patients with 
clonidine U-NAG/crea 0. (0.–0.9) units g- at baseline increased to . (0.–2.) units g- at 
60 minutes of pneumoperitoneum (mean difference at 60 minutes between the groups 0.5 units 
g-, 95% CI for difference: 0. to 0.8 units g-, p = 0.0, Mann Whitney U-test). The increase in 
U-NAG/crea was transient in both groups, and at  hours after pneumoperitoneum the concen-
trations were comparable to those observed at baseline (Figure 7). 
At baseline, before the study drug administration, the uncorrelated U-NAG was over 6. 
units L- (the highest concentration measured from healthy volunteers, Koivusalo 997) in two 
controls and one patient with clonidine. During the study period U-NAG increase over 6. units 
L- in 7/5 controls and in /5 patients with clonidine (p = 0.) (table 9). 
URINE β2-MICROGLOBULIN
The effects of ketorolac (study ) and smoking (studies  and ) on renal proximal tubular de-
terioration were evaluated with U-β2-MG	in	the	patients	with	sevoflurane	(studies	1	and	4)	and	
enflurane	anesthesia	(study	3).
Ketorolac study (study 1)
In study , U-β2-MG remained low without differences between the two groups. High U-β2-
MG, > 0.25 mg L- (Hospital district of Helsinki and Uusimaa, Huslab 2005), at baseline was 
noted in one patient with ketorolac, and during anesthesia and recovery it increased > 0.25 mg 
L- in 2/5 controls and in /5 patients with ketorolac. 
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In study , no differences were noted in U-β2-MG between the non-smokers and smokers 
(p = 0.). 
Enflurane	study	(study	3)
In study , U-β2-MG remained low without differences between the two study groups (at base-
line p = 0.6, at 2 hours p = 0.6). 
Sevoflurane	study	(study	4)
In study , the median of U-β2-MG remained low in both study groups. 
Urine β2-MG increased markedly (>  mg L-) in 2/25 non-smokers and in 2/25 smokers 
after	sevoflurane	 inhalation.	 In	a	post-hoc	analysis	 it	was	 revealed	 that	U-β2-MG increased 
significantly	in	2/5	patients	with	S-F- over 0 µmol L- compared to 2/5 patients with the high-
est S-F- less than 0 µmol L- (p = 0.005, chi-square test).
URINE GLUTATHIONE TRANSFERASE-α 
Ketorolac study (study 1)
Urine GST-α/crea	increased	in	the	patients	with	sevoflurane	anesthesia.	At	baseline	there	was	
no differences between the two groups in the median of U-GST-α/crea (p = 0.9). Urine GST-
α/crea	increased	to	its	highest	 in	both	groups	at	 two	hours	after	sevoflurane	anesthesia	(p	=	
0.001,	Wilcoxon	signed	ranks	test).	However,	after	anesthesia	it	was	significantly	lower	in	the	
controls, 0. (0.–.0) mg mol-, than that in the patients with ketorolac, .5 (0.–5.9) mg mol-, 
(mean difference .0 mg mol-, 95% CI for difference: 0.02 to 2.0 mg mol-, p = 0.06, Mann-
Whitney U-test). Urine GST-α/crea increased over .9 mg mol-, the highest ratio observed from 
healthy volunteers (Teppo A-M, personal communication 2000), in /5 controls and in 7/5 
patients with ketorolac (p = 0.068) (table 8).
DISTAL TUBULUS
URINE GLUTATHIONE TRANSFERASE-π 
Ketorolac study (study1)
In study , the effects of ketorolac on distal tubular cellular integrity were evaluated with U-
GST-π/crea	in	the	patients	with	a	3.3	MAC-hour	sevoflurane	anesthesia.	
Urine GST-π/crea increased similarly in both study groups to its maximum at two hours after 
the anesthesia; in the control patients the median of U-GST-π/crea 0. (0.0–0.5) mg mol- at 
baseline increased to 0.8 (0.–9.5) mg mol- at two hours after the anesthesia (p = 0.00, Wil-
coxon signed ranks test), and in the patients with ketorolac from 0. (0.05–.2) mg mol- at 
baseline to . (0.–6.) mg mol- at two hours (p = 0.00, Wilcoxon signed ranks test). Urine 




In study , the patients underwent mastectomy and axillary dissection (n = 9) or minor breast 
surgery	(n=	21).	Sevoflurane	was	used	for	anesthesia	maintenance	with	a	median	exposure	of	
. MAC-hour. 
The surgical bleeding was twice as low in the controls, 200 (50–650) mL (median (mini-
mum–maximum)), compared to the patients with ketorolac, 00 (200–00) mL (p = 0.00, 
Mann-Whitney U-test). The most abundant blood loss was in 2/5 patients with ketorolac, 
800 mL and 00 mL respectively, and packed red blood cells were administered in these two 
patients. No reoperations due to bleeding were performed. There was no difference in blood 
hemoglobin concentration and hematocrit between the two study groups at baseline or at 
2 hours after surgery. 
KETOROLAC AND FLUORIDE
In study , no differences in F- excretion between the two study groups were noted; in the con-
trol patients the AUCF0-8 was 60 (60–80) µmol h L- (median (minimum-maximum)) and 
in the patients with ketorolac 50 (280–200) µmol h L- (p = 0.87).
Serum F-	 increased	to	the	maximum	at	two	hours	after	sevoflurane	anesthesia	both	in	the	
controls, from .2 (2.6–.6) µmol L- at baseline to 2 (8–7) µmol L-, (p = 0.00, Wilcoxon 
signed ranks test), and in the patients with ketorolac, from .0 (.–6.) µmol L- to 26 (2–50) 
µmol L-, (p = 0.00). /5 controls and /5 patients with ketorolac had S- F- 0 µmol L- or 
higher	at	 two	hours	after	sevoflurane	anesthesia.	Serum	F- remained elevated until 8 hours 
after	sevoflurane	anesthesia	and	no	differences	between	the	two	study	groups	were	noted	(Figure	
9). 
Ketorolac had no effect on U-F-. In the control patients U-F- increased from 8 (–00) 
µmol L- at baseline to the highest of 820 (50–00) µmol L- and in the patients with ketoro-
lac from 50 (2–20) µmol L- to 900 (80–200) µmol L- at 2 hours after anesthesia. The 
urine volumes were similar in both study groups.
CLONIDINE, PNEUMOPERITONEUM AND RENAL FUNCTION
In study 2, the S-ADH and P-RA were evaluated as factors possibly affecting renal function 
during pneumoperitoneum for laparoscopic cholecystectomy. 
No differences in S-ADH were noted between the two study groups. At baseline, in the con-
trol patients, the median of S-ADH was .0 (0.–26) ng L-, and it increased to 0 (.0–220) ng 
L- at 60 minutes of pneumoperitoneum (p = 0.00, Wilcoxon signed ranks test). A similar in-
crease was noted in the patients with clonidine, S-ADH .0 (0.–) ng L- at baseline increased 
to 67 (.0–280) ng L- at 60 minutes of pneumoperitoneum (p = 0.00).
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The median of urine output in the controls was 0.6 (0.–.2) mL kg- h- and in the patients 
with clonidine .5 (0.5–.0) mL kg- h- (p = 0.06). 8/5 controls and /5 with clonidine had 
urine output 0.5 mL kg- h- or less (p = 0.005, chi square test). In the controls P-RA at 60 min-
utes of pneumoperitoneum and at 60 minutes after surgery correlated inversely with urine out-
put	at	120	minutes	after	pneumoperitoneum	(Pearson	correlation	coefficient:	–0.526,	p	=	0.044,	
and –0.62, p = 0.0, respectively).
In study 2, the clonidine-treated patients had low concentrations of P-RA during pneumoper-
itoneum. In the controls, the median of P-RA at anesthesia induction (60 minutes after the study 
drug injection) was 2. (0.2–5.) ng L- and in the patients with clonidine 0.8 (0.–.2) ng L- 
(p = 0.07). At 5 minutes of pneumoperitoneum P-RA was in the control patients 5. (0.–) 
ng L- and in the patients with clonidine . (0.5–5.7) ng L- (mean difference . ng L-, 95% 
CI for difference: .0 to 5. ng L-, p = 0.0, Mann Whitney U-test). Also, P-RA was higher in 
the controls after 0 minutes of pneumoperitoneum, 5.0 (0.–) ng L-, than in the patients 
with clonidine .7 (0.2–7.0) ng L- (mean difference .5 ng L-, 95% CI for difference: .0 to 5.9 
ng L-, p = 0.026). 
EFFECT OF SMOKING ON THE METABOLISM OF 
ENFLURANE AND SEVOFLURANE 
ENFLURANE STUDY (study )
In study  the effects of smoking on S-F-	production	after	one	MAC-hour	enflurane	anesthesia	
were evaluated in  women undergoing gynecological surgery. 
In the non-smoking group, the median of AUCF0-2 was 220 (0–50) µmol h L- and in the 
smokers the median of AUCF0-2 was between 20 (20–620) µmol h L-, (the mean difference 
0 µmol h L-, 95% CI for difference: 2 to 90 µmol h L-, p = 0.028, Mann Whitney U-test) 
after	one	MAC-hour	enflurane	anesthesia.	The	detected	S-F- had its highest concentration at six 
hours after the anesthesia in both groups; in the non-smokers S-F- increased to 2 (6.6–2) 
µmol L- (p = 0.00, Wilcoxon signed ranks test) and in the smokers to 8 (7.5–8) µmol L- 
(p = 0.00) (Figure 9). 
SEVOFLURANE STUDY (study )
In	the	sevoflurane	study	(study	4)	the	effects	of	smoking	on	S-F- production was evaluated after 
one	MAC-hour	sevoflurane	anesthesia	in	50	women	undergoing	gynecological	surgery.	
In	contrast	to	enflurane,	smoking	did	not	affect	the	F-	production	after	sevoflurane	anesthe-
sia. In the non-smokers the median of AUCF0-2 was 20 (8–70) µmol h L- and in the smok-
ers 20 (0–970) µmol h L- (the mean difference 55 µmol h L-, 95% CI for difference: –2 
to 50 µmol h L-). The individual AUCF0-2 in the non-smoking and smoking patients with 
sevoflurane	are	presented	in	figure	8	a	and	b.
The S-F-	peaked	at	two	hours	after	sevoflurane	anesthesia	in	both	groups;	in	the	non-smokers	
S-F- increased from .6 (.0–) µmol L- at baseline to 26 (8.2–0) µmol L- at two hours after 
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anesthesia (p = 0.000, Wilcoxon signed ranks test) and in the smokers from .7 (0.5–5.2) µmol 
L- to 25 (7–7) µmol L- (p = 0.000,) (Figure 0). /25 non-smokers and /25 smokers had 
S-F- 0 µmol L- or higher. 
KETOROLAC STUDY (study )
The	primary	aim	of	study	1	was	not	to	evaluate	the	effects	of	smoking	on	sevoflurane	metabo-
lism and F- production, but because both smokers (n=0) and non-smokers (n=20) were in-
cluded, in a post-hoc analysis, these two populations were compared. 
In	accordance	with	the	sevoflurane	study	(study	4),	there	were	no	differences	in	F- produc-
tion between the non-smokers, AUCF0-8 580 (60–200) µmol h L-, and the smokers, AUCF0-
8 600 (260–200) µmol h L-. /20 non-smoking patients and /0 smoking patients had the 
highest S-F- 0 µmol L- or higher (p = 0.). 
Although the depicted F-	release	after	the	3.3	MAC-hour	sevoflurane	anesthesia,	AUCF0-2 
0 (60–860) µmol h L-,	 exceeded	 that	 after	 one	MAC-hour	 sevoflurane	 anesthesia,	 320	
(80–970) µmol h L- (mean difference 99 µmol h L-, 95% CI for difference: 22 to 80 µmol h 
L-, Mann-Whitney U-test p = 0.00), F- release was not dose proportional. Fluoride production 
was	only	1.4	fold	higher	despite	3.3	time	higher	sevoflurane	exposure.
Figure	6.	Urine	α1-MG/crea	in	patients	with	ketorolac	undergoing	breast	surgery	(study	1,	publication	II).	










Figure 7. Urine NAG/crea in the patients with clonidine undergoing laparoscopic cholecystectomy (study 
2). Data are represented as means and standard deviations. * p = 0.0 (Mann.Whitney U-test). 
Figure 8a. The serum AUCF0-2	of	inorganic	fluoride	(µmol h L-) from the lowest to the highest value in 
the	non-smoking	patients	(n	=	25)	after	one	MAC-hour	sevoflurane	anesthesia.
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with and without ketorolac (control), data are means. 
Time hours
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Baseline 120 min 2 h after 
anesthesia
12 h after 
anesthesia
24 h after 
anesthesia
































































































































anesthesia. Values are not correlated to urine creatinine, data are median and (minimum-maximum) 
(study ).
* p<0.05, ** p<0.0 between the study groups (Mann-Whitney U-test), # p<0.05, ## p<0.0 comparing 
to the baseline concentration within the study group (Wilcoxon signed ranks test). U = urine, crea = 
creatinine, α-MG = α-microglobulin, GST-α = Glutathione-S-transferase -α, GST-π = Glutathione- 
S-transferase -π.
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Table 9. Urine N-acetyl-β-D-glucosaminidase and creatinine in patients with and without clonidine during 
laparoscopic cholecystectomy. Values are not correlated to urine creatinine. Data are median and (minimum-
maximum) (study 2). 




































































# p<0.05 compared to the baseline within the study group. 0 min = 0 minutes of pneumoperitoneum, 60 












been presented. In previous studies, a decrease in crea clearance (Freedland et al. 2002, Lee et 
al. 200) has been shown in patients with perioperative NSAID. However, crea clearance cal-
culated with the Cockcroft-Gault equation (Cockcroft and Gault 976) used by Freedland and 
co-workers (2002) is susceptible to errors from patients’ age, gender and weight (Verhave et al. 
200). Serum cystatin C and S-β2-MG measurements used in the present study are more sensi-
tive and reliable markers of glomerular function and less affected by the patient characteristics 
(Harmoinen 200, Harmoinen et al. 200).
There are some differences in the study designs, which may explain the contradictory results. 
The dosage of ketorolac (.8 mg kg-) was higher in the Freedland and co-workers (2002) study 
than that in the present study (. mg kg-). Moreover, in the Freedland’s study the anesthesia 
and	 the	fluid	 therapy	were	not	 reported,	 leaving	unanswered	possible	hypotension	or	hypo-
voelemia as risk factors for ARF in addition to NSAID (Wilson and Aronson 200). In the 
present	 study,	 the	 lower	 dose	 of	 ketorolac	 and	 sufficient	 fluid	 therapy	may	have	 prevented	
	abundant	 glomerular	 deterioration	 in	 patients	 undergoing	 breast	 surgery	 with	 sevoflurane	
 anesthesia.
In summary, ketorolac 90 mg, did not affect renal glomerular function in patients undergoing 
3.3	MAC-hour	sevoflurane	anesthesia.
PROXIMAL TUBULAR FUNCTION
If compared with the reference values obtained from healthy volunteers, U-α-MG/crea ap-
peared to be an unreliable indicator of the proximal tubular dysfunction in patients having 
breast surgery. In study , U-α-MG/crea was higher than the upper limit of normal, > 0.7 g 
mol-	(Teppo	et	al.	2000),	in	one	fifth	of	the	patients	undergoing	breast	surgery	already	at	base-
line. Moreover, U-α-MG/crea was > 0.7 g mol- at some state of the perioperative period in 
almost all patients in the ketorolac study. Therefore, it remains unanswered whether the patients 
had actually developed a proximal tubular dysfunction or whether the observation was biased 
due to an unreliable method. 
The present study indicates that perioperative ketorolac may not be harmful for proximal 
tubular	function	in	patients	with	sevoflurane	anesthesia	if	a	sufficient	fluid	therapy	is	provided.	
In the present study, a small increase in U-α-MG/crea was noted in the controls but no such 
increase was noted in the patients with ketorolac, and at 8 hours after anesthesia, fewer pa-
tients with ketorolac had U-α-MG/crea > 0.7 g mol- than controls. 
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However, further studies are warranted in surgical patients to establish the reference values 
for U-α-MG/crea and to establish the reliability of U-α-MG/crea as a marker of proximal 
tubular function. The invasiveness of surgery may also affect U-α-MG/crea excretion. In the 
present	study,	the	patients	had	breast	surgery	and	no	clinically	significant	increase	in	U-α-MG/
crea was noted, whereas, in patients undergoing coronary artery bypass grafting surgery, U-α-
MG	increased	significantly	and	remained	elevated	for	several	days	after	surgery	(Gormley	et	al.	
2000, Boldt et al. 200). 
In summary, with the reference values obtained from healthy volunteers in surgical patients, 
U-α-MG/crea is an unreliable marker of proximal tubular function and reference limits of 
U-α-MG/crea are yet to be established in surgical patients.
PROXIMAL TUBULAR CELLULAR DAMAGE
3.3	MAC-hour	sevoflurane	anesthesia	may	induce	some	degree	of	injury	in	proximal	tubular	
cells. In the present study U-GST-α/crea and U-NAG/crea increased in all patients having 
sevoflurane	and	isoflurane	anesthesia.	However,	the	injury	caused	by	sevoflurane	may	be	ag-
gravated	by	a	concomitant	administration	of	ketorolac.	After	sevoflurane	anesthesia	(study	1),	
the median of U-GST-α	was	significantly	higher	in	the	patients	with	ketorolac	than	in	the	con-
trols. Also, the proportion of patients with U-GST-α higher than that obtained from healthy 
volunteers was greater in the ketorolac group than in the controls (Teppo personal communica-
tion 2000). 
Also, the uncorrelated U-NAG increased more than that obtained from healthy volunteers, 
6. units L-,	in	5/15	patients	with	ketorolac	having	3.3	MAC-hour	sevoflurane	anesthesia	but	
in	none	of	the	controls,	indicating	that	during	sevoflurane	anesthesia	ketorolac	may	have	harm-
ful effects on proximal tubular integrity. There were no differences in other biomarkers of 
proximal tubular damage between the two study groups; U-β2-MG remained at low concentra-
tions during the length of the study period both in the patients with ketorolac and in the controls. 
Serum F- does not seem to be the reason for increased U-NAG/crea or U-GST-α/crea, as there 
was no correlation between these biomarkers and the rise in S-F-. 
Supporting the results of the present study, Higuchi and co-workers (995) noted an increase 
in	U-NAG/crea	after	9–11	MAC	hour	sevoflurane	anesthesia.	However,	there	are	some	differ-
ences between the two studies. Higuchi measured the highest U-NAG/crea concentrations at 8 
hours after the surgery compared to maximum U-NAG/crea at two hours in the present study. 
In the Higuchi-study U-NAG/crea was still elevated 72 hours after surgery while in the present 
study U-NAG/crea decreased to the baseline at 2 hours after surgery.
In	accordance	to	the	present	result,	a	significant	increase	in	U-GST-α was demonstrated at 
24	and	at	48	hours	after	10	MAC-hour	sevoflurane	anesthesia	in	a	volunteer	study	(Eger	et	al.	
997). Contradictory results on inhalation anesthetics effects on sensitive biomarkers of proxi-
mal	tubular	cellular	damage	have	been	reported.	In	Kharasch	and	co-workers'	study	(1997),	no	




lular deterioration, noted as increased urine release of U-NAG/crea and -GST-α/crea in the 




cellular integrity. In study , a slight increase in U-GST-π/crea was noted after . MAC hour 
sevoflurane	anesthesia,	but	U-GST-π/crea remained below the reference limit of 7. mg mol- 
(Teppo personal communication 2000) in all except one patient. This is in agreement with 









rioration and co-administration of clonidine may enhance the damage. In the present study, 
more patients with clonidine than controls had the uncorrelated U-NAG in excess of the highest 
reference concentration obtained from healthy volunteers (6. units L-, Koivusalo 997). How-
ever, although U-NAG, which is a sensitive marker of proximal tubular damage, increased 
during	pneumoperitoneum	in	the	patients	with	isoflurane,	U-NAG	concentrations	were	not	sig-
nificantly	higher	than	those	observed	in	the	ketorolac	study	in	the	patients	having	sevoflurane	
anesthesia for breast surgery (study ). 
An	IAP	exceeding	15	mmHg	reduces	renal	cortical	blood	flow	by	40%	and	decreases	GFR	
in an experimental trial (Chiu et al. 995). With IAP of 2 mmHg, urine output decreases and 
U-NAG obtained at the end of surgery is a third higher (Koivusalo 997) compared with the 
present study. In humans there are no studies comparing effects of different IAPs on proximal 
tubular deterioration. In an experimental model in rats, IAP of 5 mmHg did not affect GFR, but 
with an IAP of 0 mmHg both GFR and urine output decreased (Lindström et al. 200). There-
fore, it remains to be established whether pneumoperitoneum with IAP 2 mmHg used in the 
present study induces	any	significant	proximal	tubular	deterioration	per se.
Micali and co-workers (999) have evaluated the effects of pneumoperitoneum on proximal 
tubular integrity and they reported U-NAG/crea concentrations which were 5-fold higher than 
those found in the present study. There are some differences between the two studies that may 
explain	the	conflicting	findings.	In	the	Micali	and	co-workers	(1999)	study,	some	patients	had	
renal diseases and malignancies or nephrotoxic antibiotic therapy, which may have affected U-
NAG/crea levels. 
Clonidine may compromise renal perfusion during pneumoperitoneum by decreasing heart 
rate, blood pressures and cardiac output (Kallio et al. 990). The dose response of clonidine’s 
hemodynamic effect is U-shaped: with both small, –2 µg kg-, and high, 6–8 µg kg-, doses 
rarely leading to hypotension in patients with clonidine. With moderate doses, as the dosage 
6
.5 µg kg-	used	in	the	present	study,	the	blood	pressure	decrease	is	most	significant	(Lowenthal	
980, Eisenach et al. 996). At a dose of 2 µg kg- intravenous clonidine does not decrease 
cardiac index below 2 L min- m-2 (Kallio et al. 990), which is considered to be a critical limit 
for renal perfusion during laparoscopic surgery, but with a medium dose  µg kg- low cardiac 
index	may	ensue	(Kallio	et	al.	1990).	Therefore,	in	the	present	study,	the	renal	blood	flow	and	
perfusion pressure may have been low during pneumoperitoneum causing the minor proximal 
tubular deterioration.
In	summary,	pneumoperitoneum	and	isoflurane	anesthesia	seems	to	cause	a	transient	proxi-
mal tubular cellular deterioration and co-administration of clonidine may enhance the damage.
ANTIDIURETIC HORMONE
In the present study (study 2), clonidine prevented the effect of ADH on the renal collecting 
tubules permeability and urine output, as only /5 patients with clonidine compared to 8/5 
controls developed oliguria, urine output ≤ 0.5 mL kg h-, which is the commonly accepted 
limit (Bellomo et al. 200) for a risk of renal deterioration. Similar diuretic effects of clonidine 
have also been reported by other groups (Gellai and Edwards 988, Hamaya et al. 99). 
PLASMA RENIN ACTIVITY
Plasma RA increases during laparoscopy (Joris et al. 998). In the present study (study 2), clo-
nidine	premedication	diminished	significantly	the	increase	in	P-RA	in	patients	having	pneu-
moperitoneum for laparoscopic cholecystectomy. Two experimental studies (Reid et al. 975, 
Nolan and Reid 978) and a human study (Lenaerts et al. 200) have shown a similar effect of 
clonidine on P-RA. 
Increased P-RA induces a production of angiotensin II, which is a potent vasoconstrictor. 
The released angiotensin II and catecholamines, particularly noradrenaline mediate the vaso-
constriction and increased blood pressure during pneumoperitoneum (Joris et al. 998). In study 
2, a positive correlation was noted with mean arterial pressure and P-RA supporting earlier stud-
ies (Reid et al. 975). The serum catecholamine concentrations are lower in clonidine-treated 
patients than in patients not receiving clonidine (Quintin et al. 99, Joris et al. 998). How-
ever, in the present study, S-catecholamines were not measured, and thus, the possible relation-
ship between catecholamines and increased blood pressures and heart rate noted in the present 
study remains unclear.
In summary, clonidine administration before pneumoperitoneum induces minor and transient 
proximal tubular cellular damage during laparoscopic cholecystectomy. However, the effects in 










ers F-	production	from	enflurane,	serum	AUCF0-2 98 µmol h L-, was one third less than in the 
non-smokers	with	sevoflurane,	serum	AUCF0-2 7 µmol h L-.
There	 were	 two	 factors,	 which	 may	 have	 affected	 the	 biodegradation	 of	 enflurane	 and	
sevoflurane	(Study	3,	4).	The	activity	of	CYP	450	isoenzymes	varies	between	individuals	(Piao	
et al. 200) and it is known that in patients with low activity of CYP 2E S-F- remains at mod-
erate	concentration	after	sevoflurane	anesthesia,	while	in	the	patients	with	high	CYP	2E1	activ-
ity S-F-	increases	significantly	(Wandel	et	al.	1997).	In	the	present	study	the	CYP	activity	was	
not tested, but an uneven distribution of activity between the non-smokers and the smokers 
seems unlikely. Propofol was used for anesthesia induction and for maintenance after inhalation 
anesthesia. Propofol inhibits the CYP 2E (Wandel et al. 997, Lejus et al. 2002), and thus 
propofol	infusion	may	have	decreased	metabolism	of	sevoflurane	and	release	of	F-. However, 
the amount of propofol used in the present trial was similar across the study groups (studies  
and ) making them comparable with each other. Whether propofol supplementation could 
protect	patient	at	risk	from	renal	failure	during	sevoflurane	anesthesia	remains	unknown	and	
needs further studies.
In summary, cigarette smoking increases release of F-	in	patients	with	enflurane	anesthesia	
but does not affect F-	production	with	sevoflurane	anesthesia.	
EFFECT OF ENFLURANE AND SEVOFLURANE ON  
GLOMERULAR FUNCTION 
The inhalation anesthetic agents and their metabolite, F-, induce renal deterioration. Based on 
experiences	with	methoxyflurane,	the	renal	toxic	threshold	of	S-F- was suggested to be 50 µmol 
L- (Taves et al. 970, Cousins and Mazze 97). However, decreased crea clearance and de-
fects in renal concentrating ability has been reported with lower S-F-,  µmol L-, after 9.6 
MAC-hour	enflurane	anesthesia	in	volunteers	(Mazze	et	al.	1977).	Therefore,	it	seems	that	not	
only the maximum S-F-, but also the extent (concentration x time) of F- exposure is important. 
This is supported by the literature that indicates that both the AUCF and the amount of intrare-
nal metabolism of inhalation anesthetic may be determinants in renal toxicity (Kharasch et al. 
1995b,	Malan	1995).	In	the	case	of	methoxyflurane,	the	duration	of	F- exposure is prolonged 
because	methoxyflurane	is	highly	tissue	soluble	and	released	slowly	for	metabolism.	Due	to	the	
high tissue solubility and high proportion of metabolism (0–75%), S-F- remains elevated for 
four	to	six	days	after	the	methoxyflurane	anesthesia	(Kharasch	1995).	Methoxyflurane	is	me-
tabolized actively in the kidneys and the rate of metabolism is four times higher than that of 
sevoflurane	(Kharasch	et	al.	1995b).
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Serum tumor associated trypsin inhibitor
In the present study, lower S-F- than the previously supposed limit of 50 µmol L- for tubular 
toxicity (Cousins and Mazze 97) caused glomerular dysfunction measured with S-TATI 
(study	4).	After	enflurane	anesthesia,	4/33	patients	and	after	sevoflurane	anesthesia,	11/50	pa-
tients developed high S-TATI (over  nmol L-).	In	the	sevoflurane	study,	5/11	patients	with	
pathological S-TATI had S-F- 0 µmol L- or above.
Some patients developed glomerular dysfunction after gynecological surgery with one MAC-
hour	sevoflurane	anesthesia	(study	4)	but	GFR	remained	stable	in	all	study	patient	after	breast	
surgery	with	3.3	MAC-hours	sevoflurane	anesthesia	(study	1).	Two	factors	may	explain	differ-
ences in GFR. Firstly, hydration during the operation day was slightly less in the patients under-
going gynecological surgery, 50 mL kg-, than in patients undergoing breast surgery, 65 mL 
kg-. Secondly, different methods of measuring GFR were used; S-TATI was used in the patients 
undergoing gynecological surgery and S-cystatin C and -β2-MG in the patients undergoing 
breast surgery. Serum cystatin C is a reliable and sensitive marker of mild glomerular dysfunc-
tion (Wasén 200), but S-TATI may not be as appropriate marker of GFR in gynecological pa-
tients because S-TATI may increase in the patients with e.g. ovarian tumors and pelvic infec-
tions without any disturbance in renal function (Paavonen et al. 989, Stenmann 2002). In the 
present	study,	the	five	patients	with	high	S-TATI	and	S-F- did not have known confounding fac-
tor for increased S-TATI.




In the present study (studies , ) the proximal tubular effect of F- was assessed with U-β2-MG. 
After	 enflurane	 anesthesia	 U-β2-MG	 remained	 at	 low	 concentrations	 but	 after	 sevoflurane	
 anesthesia U-β2-MG increased in two patients, both had a high S-F-, 0 and 7 µmol L-. 




line six days after surgery (Tsukamoto et al. 996). 
In summary, in addition to glomerular dysfunction also a transient tubular dysfunction may 
occur at S-F- of 0 µmol L- or above, which is lower than the previously suggested renal toxic 
concentration of 50 µmol L- (Cousins and Mazze 97).
SURGERY
PNEUMOPERITONEUM AND TUBULAR FUNCTION
In the present study (study 2), pneumoperitoneum with IAP of 2 mmHg did not induce sig-
nificant	proximal	 tubular	deterioration,	although	a	slight	 increase	in	U-NAG/crea	was	noted	
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during pneumoperitoneum. However, the changes in U-NAG/crea were transient and the in-
creased	concentrations	returned	to	the	baseline	the	first	hours	after	pneumoperitoneum.	Glomer-
ular function, assessed with S-crea, remained stable during the operation and 2-hour follow-
up.
Renal GFR and urine output decreases during pneumoperitoneum and this impairment may 
last hours after prolonged pneumoperitoneum (Chiu et al. 995). Increased IAP causes deterio-
ration in renal perfusion pressure (Harman et al. 982), and elevated renal venous pressure is 
considered one of the mechanisms for the renal impairment (Doty et al. 2000). In the present 
study, renal venous pressure was not measured.
The type of pneumoperitoneum seems to affect NAG/crea response during laparoscopy. 
Higher U-NAG/crea is measured in patients undergoing laparoscopic surgery operated with 
conventional pneumoperitoneum, IAP of 2- mmHg with room temperature CO2, than with 
abdominal wall retractor without CO2	insufflation	(Koivusalo	1997).	
In summary, pneumoperitoneum with clonidine medication added may cause urine release 
of proximal tubular cellular deterioration biomarkers. However, in the present study the in-
crease of these biomarkers was minor and returned to baseline shortly after surgery. On the 
contrary, glomerular function is preserved.
MAIN LIMITATIONS OF THE STUDY
STUDY GROUP SIZE
The	study	group	size	in	the	first	three	studies	was	small.	In	the	1990s	when	the	first	trials	were	
conducted it was common to use this size or even smaller study populations when renal effects 
of inhalation anesthesia were investigated with sensitive renal biomarkers (Higuchi et al. 99, 
Bito and Ikeda 99, Higuchi et al. 995, Bito et al. 997, Eger et al. 997, Ebert et al. 998a). 
Based on results of the present study, it is estimated that at least 25 to 0 patients per group is 
necessary in these kinds of studies to be able to make any meaningful clinical conclusions.
TRADITIONAL AND NOVEL MARKERS OF RENAL FUNCTION
In the present study, sensitive biomarkers of renal cellular integrity and function were used. The 
use of novel renal markers has been criticized and their clinical meaning has been questioned 
(Mazze et al. 2000). The criticism by Mazze and co-workers (2000) is based on a meta-analysis 
of	22	clinical	 trials	 in	3400	patients	with	sevoflurane,	propofol,	 isoflurane	or	enflurane	 that	
shows no renal deterioration measured with S-crea and blood urea nitrogen. However, S-crea 
and blood urea nitrogen concentrations are considered insensitive markers of renal integrity and 
function (Charlson et al. 989, Kellen et al. 99). 
MEASUREMENT OF GLOMERULAR FUNCTION
Serum	crea,	S-cystatin	C,	S-β2-MG	and	S-TATI	are	used	to	assess	GFR,	but	each	of	them	has	
limitations. Serum crea is insensitive to small and rapid changes in renal function (Charlson et 
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al. 989, Kellen et al. 99). Serum cystatin C, -β2-MG and -TATI are more sensitive endog-
enous markers of glomerular function and they correlate well with crea clearance, (Harmoinen 
200, Tramonti et al. 997). However, when the renal threshold for reabsorption of β2-MG and 
TATI is exceeded (for S-β2-MG > 6000 µg L-) they are excreted into the primary urine. Intact 
proximal tubules reabsorb and degrade U-β2-MG and -TATI, but deteriorated cells release these 
markers into urine.
TUMOR-ASSOCIATED TRYPSIN INHIBITOR AND  
URINE β2-MICROGLOBULIN 
Pelvic infections and ovarian tumors present a confounding factor when assessing renal glomer-
ular function with TATI, as S-TATI may increase in both conditions (Stenmann 2002). In the 
present study (study ), two non-smoking patients with high S-TATI had a pelvic infection. 
There are some limitations in using U-β2-MG as an indicator of tubular damage. β2-mi-
croglobulin is synthesized in most nucleated cells and lymphocytes, and lymphoproliferative 
diseases like multiple myeloma (Schardijn and Statius van Eps 987) may interfere renal diag-
nostics. β2-MG is degraded at body temperature and at a pH lower than six (Schardijn and 
Statius van Eps 987), so acidic urine may lead to misleadingly low U-β2-MG levels. In the 
present study, U-pH was adjusted to 7.0 or higher according to laboratory instructions (Hospital 
district of Helsinki and Uusimaa, Huslab 2005).
α-MICROGLOBULIN
In the present study, U-α-MG/crea was an unreliable indicator of proximal tubular dysfunction 
in surgical patients because already at baseline 6/0 patients had U-α-MG/crea higher than 
upper limit of normal, 0.7 g mol-, obtained from healthy volunteers not undergoing surgery 
(Teppo et al. 2000).
SAMPLING
In the present study (study –), urine markers were collected from spot samples at predeter-
mined times. It is common to measure urine biomarkers from 2-hour collection of urine and 
indexed to U-crea or urine volume (Higuchi et al. 995, Teppo et al. 2000). However, spot sam-
ples normalized to U-crea are also used (Wellwood et al. 975). 
The correction of urine markers to U-crea is criticized because the secretion of crea changes 
according to the age of patients. The use of uncorrected markers may be better if the age of 
patients	varies	greatly.	Correction	of	renal	biomarkers	to	specific	gravity	of	urine	has	also	been	
suggested.	However,	the	specific	gravity	correlates	closely	with	U-crea	and	it	is	not	considered	
better than correction to U-crea (Moriguchi et al. 200). In the present study the age range was 
large, from 20 to 6 years, so the uncorrected values of renal markers are also presented, but the 
conclusions of the results were made from urine biomarkers normalized to U-crea.
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CLONIDINE AND CARDIAC PERFORMANCE
Impaired cardiac performance is one of the main risk factor for ARF (Wilson and Aronson 
200). Clonidine and pneumoperitoneum both reduce cardiac output (Kallio et al. 990, Hirvo-
nen et al. 997). In the present study, cardiac output was not measured, but the patients were 
kept normovolemic (median central venous pressure 7 mmHg) by the i.v. hydration, so that 
blood pressure was adequate for renal perfusion and diuresis was maintained. 
DRUG ADMINISTRATION
Administration routes and sites may have a major impact on drug pharmacokinetics. Especially 
peak concentration, time to peak concentration and elimination half-life may be affected by 
administration site (Grabinski et al. 98). 
Ketorolac and clonidine were administered intramuscularly, although the site of the injection 
was not standardized. Main sites were in the area of the deltoid or gluteus muscle. A previous 
study shows more accurate absorption from the deltoid muscle than from the gluteus muscle 
(Kentala et al. 998). Pharmacokinetic parameters of ketorolac or clonidine were not measured 
in the present study.
CLINICAL ASPECTS
Increased mortality is related to ARF in connection with surgery (Chertow et al. 998). In high 
risk patients, accurate and reliable monitoring of renal function is important and may help to 
prevent permanent renal failure. Even minor insults, if they occur repeatedly, may cause cumu-
lative	damage	to	renal	integrity	and	function	(Ronco	and	Flahault	1994).	Therefore,	specific	and	
sensitive biomarkers are needed for early detection of harmful insults.
Various	noxious	stimuli	may	harm	anatomically	and	physiologically	specific	entities	of	the	




MEASURING OF RENAL FUNCTION
Renal function is commonly measured by S-crea and S-urea, but these markers detect only one 
third of patients with renal dysfunction (Charlson et al. 989, Kellen et al. 99). The simple 
and accurate biomarker S-cystatin C may be feasible in estimating GFR (Wasén 200). Cystatin 
C is able to monitor incipient and age- and disease-related GFR impairment better than S-crea 
and calculated formulas (Wasén 200).
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INTERACTION OF NSAIDS AND SEVOFLURANE DURING SURGERY
The traditional NSAIDs, e.g. ketorolac, are used routinely as a part of multimodal analgesia to 
treat postoperative pain after surgery and this approach has been proven rather safe to the kid-
neys (Forrest et al. 2002). According to the present study, the combination of ketorolac and 
moderate	length	sevoflurane	anesthesia,	3.3	MAC-hour,	is	safe	considering	renal	function,	al-
though minor transient increase in proximal tubular markers were noted. However, preoperative 
administration of ketorolac increased bleeding and need of transfusions during breast surgery. 
CLONIDINE AND RENAL FUNCTION
Clonidine prevented activation of RAAS during cholecystectomy with CO2-pneumoperitoneum. 
Clonidine prevented the effect of ADH on collecting tubules so that diuresis increased. Slight 
increase in U-NAG/crea after clonidine as a sign of proximal tubular impairment was noted 
during	pneumoperitoneum,	although	clinically	significant	renal	deterioration	was	not	seen	in	
any of the patients. Clonidine during pneumoperitoneum may be useful to inhibit the stress 
 responses and to maintain urine output, although the use of clonidine should be further evaluated 
because of the minor proximal tubular deterioration that may result.
THE EFFECT OF SMOKING ON METABOLISM OF ENFLURANE AND 
SEVOFLURANE
Various chemicals in cigarette smoke both inhibit and induce the CYP 50 enzyme. Production 
of toxic metabolites like F- may increase in smokers during inhalation anesthesia. Smoking did 
not	affect	 the	metabolism	of	sevoflurane	but	did	increase	enflurane’s	metabolism.	Prolonged	




In summary, a nonselective NSAID may be used relatively safely in connection to . MAC-
hour	sevoflurane	anesthesia,	however,	minor	proximal	tubular	deterioration	may	be	noted	with	
ketorolac.	The	first	dose	should	be	given	after	the	surgery	in	order	to	preserve	hemostasis	during	
the procedure. Clonidine prevents the effect of ADH on renal tubuli, but causes a minor and 




S-F- 0 µmol L- or higher, which is lower than the previously assumed renal toxic threshold of 
50 µmol L-.	However,	the	changes	in	glomerular	and	tubular	function	after	short	sevoflurane	





. As indicated by novel biomarkers perioperative ketorolac, 90 mg in 2 hours, does not af-
fect renal function, but may induce minor proximal tubular deterioration in patients having 
a	3.3	MAC-hour	sevoflurane	anesthesia.
2.	 After	one	MAC-hour	sevoflurane	anesthesia	patients	with	S-F-	≥	40	µmol L- and AUCF0-2 




. Preoperative clonidine .5 µg kg- does not affect renal glomerular function but may cause 
a transient proximal tubular cellular damage in patients with pneumoperitoneum.
5. Further studies are warranted to establish the reference values for the novel biomarkers of 
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